Published in final edited form as:
Front Biosci. ; 13: 5323–5344.

Role of oxidative stress and nitric oxide in atherothrombosis

Edith Lubos, Diane E. Handy, and Joseph Loscalzo

Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, 75 Francis Street, Boston, Massachusetts 02115

Abstract

During the last decade basic and clinical research has highlighted the central role of reactive oxygen species (ROS) in cardiovascular disease. Enhanced production or attenuated degradation of ROS leads to oxidative stress, a process that affects endothelial and vascular function, and contributes to vascular disease. Nitric oxide (NO), a product of the normal endothelium, is a principal determinant of normal endothelial and vascular function. In states of inflammation, NO production by the vasculature increases considerably and, in conjunction with other ROS, contributes to oxidative stress. This review examines the role of oxidative stress and NO in mechanisms of endothelial and vascular dysfunction with an emphasis on atherothrombosis.

Keywords

Oxidative Stress; Antioxidants; Endothelial Dysfunction; Atherothrombosis; Review

2. INTRODUCTION

The generation of reactive oxygen species (ROS) is important in both normal physiology and in the pathogenesis of many diseases. The ROS include partially reduced forms of molecular oxygen, such as hydroxyl radical ($\cdot\text{OH}$), superoxide anion ($\text{O}_2^{\cdot-}$), hydrogen peroxide (H_2O_2), lipid peroxides, and hypochlorous acid (HClO). Accumulation of ROS may be accompanied by the production of reactive nitrogen species (RNS), such as the highly reactive peroxynitrite anion, a strong oxidant formed by the reaction of $\text{O}_2^{\cdot-}$ and nitric oxide (NO). Under physiological conditions, cells defend themselves against ROS damage through antioxidants that remove free radical intermediates and inhibit oxidation. An imbalance between endogenous oxidants and antioxidants results in oxidative stress, a condition that contributes to vascular dysfunction and atherogenesis (1).

Superoxide anion is generated by the one-electron reduction of oxygen by nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) oxidase, mitochondrial respiration, and other oxidoreductases, such as glucose oxidase and xanthine oxidase (2,3). The effects of $\text{O}_2^{\cdot-}$ include oxidative damage, the mediation of signal transduction leading to altered gene transcription, posttranslational modification with changes in protein function and enzyme activity ('redox signaling'), and rapid inactivation of NO, leading to endothelial dysfunction. Alterations in both the rate of formation and the extent of scavenging of $\text{O}_2^{\cdot-}$ have been

Send correspondence to: Joseph Loscalzo, M.D., Ph.D., Brigham & Women's Hospital, 75 Francis Street, Boston, MA 02115, Tel: 617-732-6340, Fax: 617-732-6439, E-mail: jloscalzo@partners.org.

Note that the International Union of Pure and Applied Chemistry (IUPAC) recommended names for peroxynitrite anion (ONOO^-), peroxynitrous acid (ONOOH), and nitric oxide (NO) are oxoperoxonitrate (1^-), hydrogen oxoperoxonitrate, and nitrogen monoxide respectively. The term, peroxynitrite, is used here to refer to the sum of both ONOO^- and its conjugated acid, ONOOH .

implicated in the vascular dysfunction observed in atherosclerosis, hypertension, diabetes mellitus, chronic nitrate tolerance, and postischemic myocardial dysfunction (4,5).

In the endothelium, NO is synthesized by the Ca^{2+} -calmodulin-dependent nitric oxide synthase (eNOS), using L-arginine, O_2 , and NADPH as substrates (6). Nitric oxide is membrane permeable and diffuses throughout the vasculature, promoting smooth muscle cell relaxation by activation of soluble guanylyl cyclase and modulation of cation channels, and, consequently, regulating vascular tone (7). Additional antiatherogenic actions of NO relate to inhibition of platelet function and inflammatory cell adhesion, promotion of fibrinolysis, and attenuation of smooth muscle cell proliferation (8). Nitric oxide and $\text{O}_2^{\cdot-}$ react in a diffusion-controlled process to produce peroxynitrite, which interacts directly with lipids, DNA, and proteins, or indirectly through downstream radical-mediated mechanisms.

In the setting of cardiac risk factors and pathological conditions such as atherothrombosis, oxidative stress is associated with impaired NO bioavailability (9-11). Endothelial dysfunction represents the earliest stage in the atherosclerotic process, and also contributes to the pathogenesis of acute vascular syndromes by predisposing to plaque rupture and intravascular thrombosis. In this review, we present an overview of oxidative stress, NO synthesis, and biological chemistry, as well as the evidence linking the pathophysiology of endothelial dysfunction and atherothrombosis.

3. REACTIVE OXYGEN SPECIES

3.1. Sources of reactive oxygen species

During aerobic respiration, mammalian cells produce energy by reducing molecular oxygen (O_2) to water (H_2O). As a natural byproduct of normal metabolism, ROS play a regulatory part in cellular function (Table 1). These highly reactive molecules have the potential to interact with and irreversibly damage proteins, lipids, and DNA; antioxidant defenses modulate their steady-state flux, thereby limiting their toxicities.

A variety of enzymatic and non-enzymatic sources of ROS, particularly of $\text{O}_2^{\cdot-}$, are present in cells of the vasculature. Endothelial cells, vascular smooth muscle cells, adventitial cells, and fibroblasts contain forms of the membrane-associated NAD(P)H oxidase enzyme complex that catalyze the one-electron reduction of molecular oxygen using NAD(P)H as an electron donor and the reduced form of b₅₅₈-type cytochrome, generating $\text{O}_2^{\cdot-}$ (Figure 1) (12-18). Stimulators of NAD(P)H oxidase includes agonists of G-protein-coupled-receptors, such as angiotensin II and endothelin-1; bradykinin; growth factors, such as thrombin, vascular endothelial growth factor, and platelet derived growth factor; and cytokines, such as tumor necrosis factor- α (TNF- α) (13,19-23). Metabolic and mechanical factors, and nutrient deprivation can also increase NAD(P)H oxidase activity (24-26). NAD(P)H oxidase activity is increased during hypoxia-reoxygenation, reperfusion, prolonged exposure to nitroglycerin, and exposure to oxidized low-density lipoprotein (ox-LDL) (27-30). Activation involves modulation of membrane-bound non-phagocytic NAD(P)H oxidase (Nox) and p22^{phox} subunit expression, and cytosolic regulatory subunits, namely p67^{phox}, p47^{phox}, p40^{phox}, and the small GTPase Rac1 (17,31). Endothelial cells contain the isoforms Nox-1, Nox-2 (gp91^{phox}), Nox-4, and Nox-5; vascular smooth muscle cells express Nox-1, Nox-4, and Nox-5; and adventitial fibroblasts and vascular smooth muscle cells from resistance arteries contain Nox-2 (32-36). Acute increase in oxidase complex formation occurs secondary to post-translational modification of regulatory subunits (p47^{phox} and Rac1) or an increase in the expression and abundance of component subunits.

Another source of vascular $\text{O}_2^{\cdot-}$ is the xanthine oxidoreductase (XOR) enzyme system, which consists of a ubiquitous metalloflavoprotein found in two forms, xanthine dehydrogenase (XD)

and the posttranslationally modified form, xanthine oxidase (XO) (3). This enzyme system is expressed on the luminal surface of the endothelium and catalyzes the oxidation of hypoxanthine to xanthine in normal purine metabolism. XD requires NAD^+ as an electron acceptor; whereas XO reduces O_2 , thereby generating $\text{O}_2^{\bullet-}$. The conversion of XD to XO occurs either through the reversible thiol oxidation of cysteinyl residues or via an irreversible proteolytic cleavage of a segment of XD that can occur during hypoxia, ischemia, or inflammation (3). In addition, xanthine oxidase can directly donate two electrons to oxygen to produce H_2O_2 . A marked increase in endothelial xanthine oxidase activity has been found following ischemia-reperfusion and hypoxia-reoxygenation (37). In hypercholesterolemic patients, the inhibition of xanthine oxidase activity with oxypurinol improved impaired vasodilation, suggesting $\text{O}_2^{\bullet-}$ production by this enzyme can substantially reduce bioavailable NO under certain pathophysiological conditions (38).

A third potential source of vascular $\text{O}_2^{\bullet-}$ in endothelial cells is the family of nitric oxide synthases (NOS) (39). The NOS enzymes are dimeric, calmodulin-dependent or calmodulin-containing cytochrome P450-like hemoproteins that combine reductase and oxygenase catalytic domains in one monomer, bear both FAD and FMN (flavin adenine nucleotide), and carry out a five-electron oxidation of one of the basic guanidino nitrogen atoms of L-arginine with the reductive aid of tetrahydrobiopterin (BH_4), producing NO and L-citrulline (40). In the presence of suboptimal concentrations of L-arginine or of the cofactor BH_4 , NOS is functionally 'uncoupled' and produces $\text{O}_2^{\bullet-}$ via one-electron reduction of molecular oxygen (41,42). Similarly, peroxynitrite may also oxidize BH_4 and thereby cause NOS uncoupling (43). Tetrahydrobiopterin repletion improves endothelial function in chronic smokers and augments NO bioactivity in normal, hypertensive, and hypercholesterolemic human subjects (44-46). Hypercholesterolemia is also associated with endothelial dysfunction in animal models as well as in human subjects (47-49). Treatment with L-arginine attenuates endothelial dysfunction in animal models; however, the ability of L-arginine to improve endothelial function in hypercholesterolemic or other human subjects is less clear, with some studies finding a benefit whereas others fail to show improvement in endothelial responses following L-arginine treatment (50-53). Peroxynitrite can also uncouple NOS by oxidizing cysteines involved in the zinc-thiolate cluster, releasing zinc and disrupting functional dimer stability (54).

Another mechanism of endothelial dysfunction that relates to eNOS substrate availability is the *in vivo* presence of NOS inhibitors, most importantly asymmetric dimethyl arginine (ADMA), a naturally occurring guanidino-substituted analog of L-arginine (55,56). Elevated ADMA levels have been demonstrated in hyperhomocysteinemia, hypercholesterolemia, hypertension, atherosclerotic disease, and peripheral vascular disease, and correlate inversely with brachial artery flow-mediated vasodilation (57,58).

Additional intracellular sources of ROS in the endothelium include an isoenzyme of cytochrome P450 (endothelium-derived hyperpolarizing factor synthase), cyclooxygenases, lipoxygenases, aldehyde oxidase, flavin dehydrogenases, and mitochondrial respiration (59-61). The mitochondrial electron transport chain produces $\text{O}_2^{\bullet-}$ by incomplete reduction of O_2 , mainly at complex I (NADH coenzyme Q reductase) and complex III (ubiquinol cytochrome *c* reductase) (61-62). These mitochondrial sites may also be important participants in oxygen sensing vascular redox signaling (63). Increased mitochondrial $\text{O}_2^{\bullet-}$ generation in endothelial cells appears to be particularly prominent in diabetes, ischemia-reperfusion injury, and hypoxia-reoxygenation (64-65).

3.2. Effects of reactive oxygen species in the vasculature

At physiological pH, $\text{O}_2^{\bullet-}$ is both a free radical and an anion (pKa 4.8) (66). Owing to its charge, $\text{O}_2^{\bullet-}$ can be transported across biological membranes by anion channels, while its free

radical character causes it to react with other radicals in the range of diffusion-controlled reactions (66). Its ability to participate in either electron-accepting oxidation reactions (with sulfhydryl groups, ascorbic acid, NADPH) or electron-donating reduction reactions (with cytochrome *c*, metal ions) influences the vascular signaling system.

Superoxide anion reacts with itself to form H_2O_2 and O_2 by spontaneous ($k \sim 5 \times 10^5 \text{ M}^{-1} \cdot \text{s}^{-1}$ at pH 7.4) and enzymatic dismutation reactions (Figure 2) (67). The spontaneous dismutation rate is second order with respect to $\text{O}_2^{\bullet -}$ concentration. Basal levels of H_2O_2 appear to regulate some signaling systems thought to participate in oxygen and redox sensing, or are reduced to H_2O_2 by peroxiredoxins, glutathione peroxidases, or catalase (68). By the metal-catalyzed Fenton reaction, H_2O_2 forms the highly reactive $\bullet\text{OH}$, which is the strongest oxidizing agent known and reacts with organic molecules at diffusion-limited rates. Hydroxyl radical can modify amino acids, carbohydrates, lipids, and nucleic acids (69). Theoretically, owing to its interaction with ferrous complexes, NO prevents the formation of $\bullet\text{OH}$ by limiting the Fenton reaction (70,71). Hydroxyl radical-induced endothelial injury inhibits both the production and activity of NO. Thus, NO and oxygen or oxygen-derived radicals can modulate NO bioactivity (72). Nitric oxide can be oxidatively inactivated to nitrite (NO_2^-) (in a third-order reaction with O_2 that is second-order in NO) and nitrate (NO_3^-), oxidation products that have been considered to be devoid of vasodilatory activity at physiological concentrations (73). Recent studies, however, suggest NO_2^- at physiological concentrations may function as a vasodilator, perhaps due, in part, to the nitrite reductase function of deoxyhemoglobin, or to the spontaneous reduction to NO under acidic, relatively hypoxic conditions in ischemic tissues (74-75).

Reactive oxygen species can potentiate vascular dysfunction. In small cerebral arteries, impairment of endothelial function by excessive production of free radicals during acute hypertension sets the stage for increased reactivity to vasoconstrictor stimuli and the production of contractile prostanoids (PGG_2 , PGH_2) in endothelial cells as well as in smooth muscle cells via oxidation of the ferric heme of cyclooxygenase (76-78). In arteries obtained from diabetic animals, decreased endothelium-dependent relaxation appears to be linked to enhanced release of $\text{O}_2^{\bullet -}$ owing to excessive activation of arachidonic acid metabolism via cyclooxygenase (79,80).

In angiotensin II-mediated hypertension, NAD(P)H oxidase activity plays an important role as a source of ROS and mediator of elevated blood pressure; both hypertension and NAD(P)H oxidase activation can be prevented by administration of the AT_1 -receptor antagonist losartan (4,81). Other studies have shown that the expression of angiotensin converting enzyme (ACE) is increased in atherosclerotic plaque, potentially resulting in increased local production of angiotensin II. ACE-inhibitors may act as antioxidants, in part, by limiting angiotensin II-mediated $\text{O}_2^{\bullet -}$ production, thereby decreasing blood pressure and improving vascular dysfunction (82,83).

Reactive oxygen species may also modulate normal signaling pathways at multiple levels from membrane receptors and channels to various protein kinases and nuclear transcription factors (84,85). An increase in $\text{O}_2^{\bullet -}$ production is associated with an increase in cytoplasmic Ca^{2+} by enhanced extracellular Ca^{2+} influx and intracellular inhibition of Ca^{2+} uptake by the sarcoplasmic reticulum (86). In smooth muscle cells, $\text{O}_2^{\bullet -}$ can inhibit inositol 1,4,5-triphosphate-sensitive responses of the sarcoplasmic reticulum Ca^{2+} -ATPase, which inhibits Ca^{2+} uptake (87). An increase in Ca^{2+} influx is a consequence of the reaction between ROS and thiol groups of the L-type Ca^{2+} -channels or by reaction with thiol-containing cysteine-rich groups of protein kinase C (PKC) (88). Activation of PKC regulates L-type Ca^{2+} -channels by phosphorylation (89). An increase in intracellular Ca^{2+} concentration stimulates peroxynitrite formation, which may account for thiol group oxidation (nitrosation) of sarcoplasmic reticulum cysteinyl side chains. In addition, ROS decreases voltage-dependent K^+ current

density, possibly by oxidation of a methionine residue on the K⁺ channel protein of coronary artery smooth muscle cells, leading to impairment of vascular function (90-91). Similarly, ROS also inhibits ATP-dependent K⁺ currents in cardiac myocytes (92).

Oxidant species control several other signaling mechanisms in the vasculature, including soluble guanylyl cyclases (sGC), prostaglandin production, ceruloplasmin, myeloperoxidase, and tyrosine kinase regulated systems (93-95). In smooth muscle cells, a prooxidant state promotes stimulation of mitogen activated protein kinases (p42/p44 MAPK or ERK 1/2) and tyrosine kinases (protein kinase B), which leads to cell growth and migration (13,31). Stimulation of vascular smooth muscle cells by the mitogen platelet derived growth factor increases intracellular production of H₂O₂ and tyrosine phosphorylation; antioxidants, such as catalase and *N*-acetylcysteine, have been shown to modulate this activation (1,96). In the vasculature, this signaling pathway leads to hypertrophy and intimal thickening contributing to the progression of hypertension, to an increase in adhesion molecule expression, and to the development of atherosclerosis (11).

4. ANTIOXIDANTS

A paradox of metabolism is that while the vast majority of complex life requires oxygen for its existence, molecular oxygen is a highly reactive molecule that can damage living organisms by conversion to its partially reduced forms, the ROS (97). Consequently, organisms contain a complex network of low-molecular-weight antioxidant molecules and specific antioxidant enzymes that modulate redox state and prevent oxidative damage of cellular components. In general, antioxidant systems either prevent ROS from being formed, or remove them before they can damage vital components of the cell (98). Nonenzymatic antioxidant molecules in endothelial cells include uric acid, ascorbic acid (vitamin C), alpha-tocopherol (vitamin E), and glutathione (GSH), and are classified as hydrophilic or lipophilic (membrane-associated) (Table 2) (99).

Ascorbic acid is a water soluble monosaccharide that is maintained in its reduced form by GSH in a reaction that can be catalyzed by protein disulfide isomerase and glutaredoxins (100). Ascorbic acid scavenges ROS but, through its reductive effect on metal ions, can also contribute to free radical formation via the Fenton reaction (101-102). Ascorbic acid has a favorable redox couple that protects vitamin E and GSH from oxidation. In clinical studies, ascorbic acid supplementation improves NO-dependent vasodilation in human subjects with coronary artery disease, hypertension, hypercholesterolemia, and diabetes mellitus (103,104).

Vitamin E is a lipid soluble, chain-breaking radical scavenger family of eight related tocopherols and tocotrienols, and is considered the most important antioxidant in cell membranes (105). Of the various forms, alpha-tocopherol has the highest bioavailability and protects cell membranes against oxidation by reacting with lipid radicals produced during lipid peroxidation chain reactions (105,106). Oxidized alpha-tocopheroxyl radicals produced in this process may be recycled back to the active, reduced form through reduction by ascorbate, retinol, or ubiquinol (107). The function of the other forms of vitamin E are less well-studied, although gamma-tocopherol is a nucleophile that may react with electrophilic mutagens, and tocotrienols may have a specialized role in neuroprotection (106,108). Vitamin E may also have nonantioxidant cell signaling functions by modulating the activity of several enzymes involved in signal transduction (109). Owing to the antioxidant properties of vitamin E, vitamin E may improve endothelial function and reduce cardiovascular risk. Despite an initial small study demonstrating a therapeutic benefit of vitamin E on reducing non-fatal myocardial infarction, more recent, placebo-controlled, large-scale trials of antioxidants have been disappointing and have found no clinically beneficial effects of long term vitamin E supplementation (110-113).

GSH is the major low-molecular-weight cysteine-containing peptide found in most forms of aerobic life, and is synthesized in cells from its constituent amino acids (114-115). Glutathione has antioxidant properties as the thiol group in its cysteinyl moiety can be reversibly oxidized. In endothelial cells, GSH serves as a substrate for glutathione peroxidases to eliminate lipid hydroperoxides and H_2O_2 , whereby it becomes oxidized to GSH disulfide (GSSG) (116). Depletion of endogenous GSH in ischemia-reperfusion and hypercholesterolemia may also alter the vascular wall's ability to detoxify peroxynitrite (117).

Important endothelial antioxidant enzymes include the superoxide dismutases (SODs), catalase, the thioredoxin system, peroxiredoxins, the glutathione peroxidases, and heme oxygenase. The SODs convert $\text{O}_2^{\bullet-}$ to H_2O_2 which is then reduced to H_2O by peroxiredoxins, catalase, or glutathione peroxidases; superoxide can also undergo spontaneous dismutation ($k \sim 5 \times 10^5 \text{ M}^{-1} \cdot \text{s}^{-1}$ at pH 7.4). Vascular tissue contains three isoforms of SOD that enzymatically accelerate the dismutation of $\text{O}_2^{\bullet-}$ ($k \sim 2 \times 10^9 \text{ M}^{-1} \cdot \text{s}^{-1}$) (66,118-121). SODs contain metal ion cofactors that, depending on the isoenzyme, can be copper, zinc, manganese, or iron. Lack of metal ion binding can lead to significant enzyme instability, resulting in reduced enzyme levels and activity (122). Naturally occurring mutations of SOD and H_2O_2 -mediated oxidation have been shown to interfere with metal ion binding, thereby reducing enzyme function and contributing to a pathological state (123).

Healthy cells can control the intracellular formation of $\text{O}_2^{\bullet-}$ through the activities of cytosolic Cu,Zn-SOD (SOD 1) and mitochondrial Mn-SOD (SOD 2) (124). Cu,Zn-SOD expression is upregulated by shear stress and the cellular redox state (125). Mn-SOD expression is also redox-sensitive and can be induced by vascular endothelial growth factor via the activation of NAD(P)H oxidase. The extracellular form of Cu,Zn-SOD (EC-SOD or SOD 3) is produced by smooth muscle cells, tightly binds to heparan on the exofacial plasma membrane, and is particularly abundant in the interstitium of the arterial wall (126). Extracellular superoxide dismutase may be crucial for the vasodilating activity of extracellular NO by controlling the levels of extracellular $\text{O}_2^{\bullet-}$ and preventing the formation of peroxynitrite. The balance between the $\text{O}_2^{\bullet-}$ -producing oxidases and SOD activities keeps basal $\text{O}_2^{\bullet-}$ concentrations below the range in which this species can directly interfere with vascular signaling (85).

Catalase is a highly catalytically efficient enzyme that reduces H_2O_2 to water using either an iron or manganese cofactor (127). Catalase is mostly limited to peroxisomes located adjacent to mitochondria, and is expressed in higher levels in smooth muscle cells than endothelial cells (128).

Peroxiredoxins (Prx) represent a unique type of peroxidase that catalyze the reduction of H_2O_2 , organic hydroperoxides, as well as peroxynitrite (129). Mammalian cells express six isoforms of Prx, which are classified into three subgroups (2-Cys, atypical 2-Cys, and 1-Cys) based on the number and positions of Cys residues that participate in catalysis (130). All Prx enzymes share the same basic catalytic mechanism in which a redox-active cysteine (the peroxidatic cysteine) in the active site is oxidized to a sulfenic acid by the peroxide substrate and then is reduced by a thiol-dependent mechanism during the catalytic cycle. During catalysis, the active site cysteine is occasionally overoxidized to cysteine sulfinic acid (131). In fact, the susceptibility of this active site cysteine to irreversible oxidation accounts for the limited efficiency of peroxiredoxins in eliminating peroxides, which is generally confined to concentrations of H_2O_2 below 20 μM . The thioredoxin/thioredoxin reductase system regenerates the active cysteine site in peroxiredoxins (132,133). Thioredoxins also reduce disulfides in proteins, peptides, and GSSG, as well as directly lower ROS levels through their conserved -Cys-Gly-Pro-Cys- active site sequence (132,134). The active site disulfide in thioredoxin is itself reduced by the selenoprotein thioredoxin reductase and NAD(P)H (135). Thioredoxin also has redox-sensitive signaling functions through stimulation of DNA-binding

of nuclear factor kappa B (NFkappaB (p50 subunit)), increasing activator protein-1 (AP-1) binding activity (redox factor-1 (Ref-1)), and binding to the MAPKK kinase ASK1 (132). Thioredoxin expression is induced by oxidative stress.

In contrast to the peroxiredoxins, the glutathione peroxidases (GPxs) catalyze the reduction of H₂O₂ and organic hydroperoxides to alcohols using GSH as a reductant (136). In addition, these selenoproteins have a unique GSH-dependent ability to catalyze the reduction of peroxynitrite (137). This class of enzymes includes GPx-1, which is ubiquitously expressed in cytosol and mitochondria of all cells; GPx-3, which is the most abundant extracellular antioxidant enzyme; and GPx-4 or phospholipid glutathione peroxidase, which is also widely expressed and reduces membrane phospholipid hydroperoxides. In addition, the glutathione *S*-transferases are another class of glutathione-dependent antioxidant enzymes that can inactivate lipid peroxides, although their importance in the vasculature is less well understood (114, 138).

Heme oxygenase has indirect antioxidant effects through degradation of free heme and the production of CO, as well as biliverdin and bilirubin, which themselves have antioxidant properties (139). There are two isoforms of this enzyme, a constitutive heme oxygenase, HO-2, which is ubiquitously expressed in endothelial cells, and HO-1, which is induced in response to oxidative stress.

5. NITRIC OXIDE

5.1. Role of nitric oxide in the vasculature

Nitric oxide is an omnipresent signaling molecule with a short half-life that either acts within the source cell or diffuses from the source cell to affect adjacent cells (140). The targets of NO depend on the environment and on the quantity produced (141). Nitric oxide is an uncharged free radical composed of seven electrons from nitrogen and eight electrons from oxygen (142-144).

The local level of NO is determined by the balance between its rate of formation or exogenous production (e.g., cigarette smoke, medication), and its rate of inactivation (145). Nitric oxide is produced by a variety of mammalian cells, including vascular endothelium, neurons, smooth muscle cells, macrophages, neutrophils, platelets, and pulmonary epithelium (146). The physiological actions of NO range from modulating the vascular system (blood flow, inhibition of platelet adherence/aggregation, angiogenesis), to regulating the immune system (cellular immunity by macrophage, neutrophil killing of pathogens, non-specific host defense) and controlling neuronal functions (neurotransmission, synaptic plasticity in the central nervous system, oscillatory behaviour of neuronal networks) (146-147).

Under physiological conditions, NO formation is stimulated by shear forces acting on the vascular endothelium generated by flowing blood or by agonist activation of endothelial receptors (148-149). Based on this stimulation, Ca²⁺ influx triggers the enzymatic activation of constitutively expressed endothelial membrane-bound NOS (cNOS; eNOS; NOS III).

Bacterial endotoxins and inflammatory cytokines, such as TNF-alpha and interleukins, activate the inducible NOS (iNOS; NOS II), which produces Ca²⁺-independent NO at a rate 1,000-fold greater than that of eNOS (150). In the vasculature, iNOS can be induced in infiltrating macrophages and lymphocytes, endothelial cells, smooth muscle cells, or fibroblasts, whereas eNOS is predominantly produced in endothelial cells. In addition, there is a neural NOS (nNOS; NOS I) that primarily produces NO as a transmitter in the brain and in the peripheral nervous system, such as in non-adrenergic, non-cholinergic (NANC) autonomic nerves that innervate penile erectile tissue and other specialized tissues in the body to promote vasodilation (151).

5.2. Control of nitric oxide levels in vascular tissue

5.2.1. The bioreactivity of nitric oxide—After formation of NO by eNOS in the vascular endothelium, NO binds to the iron (III) hemes of cytochrome *c* oxidase in mitochondria, regulates certain transcription factors such as hypoxia-inducible factor-1 (HIF-1), or rapidly diffuses into the blood (143). In the vascular lumen, NO is readily scavenged by erythrocytes in which it reacts with the ferrous iron (Fe^{2+}) in the heme moiety of oxyhemoglobin to form met-hemoglobin and nitrate (NO_3^-) (144,152). Nitric oxide also diffuses into the vascular smooth muscle cells adjacent to the endothelium where it modulates the activity of heme-containing soluble guanylyl cyclase (sGC). This enzyme dephosphorylates guanosine triphosphate (GTP) to produce cyclic guanosine 3',5'-cyclic monophosphate (cGMP), which activates K^+ channels and inhibits Ca^{2+} entry into smooth muscle cells by directly inhibiting voltage-gated Ca^{2+} channels, and activates protein kinases that phosphorylate myosin light chains and phosphorylate sarcoplasmic proteins, leading to the sequestration of Ca^{2+} in the sarcoplasmic reticulum (153-154). The reduction in cytosolic Ca^{2+} concentration affects phosphorylation of the regulatory myosin light chains and ultimately promotes smooth muscle cell relaxation (155).

Theoretically, NO can exist in three closely related redox forms: the free radical $\text{NO}^\bullet$; NO^+ or nitrosonium, resulting from a one-electron oxidation of $\text{NO}^\bullet$; and NO^- or nitroxyl anion, resulting from a one-electron reduction of $\text{NO}^\bullet$. Nitrogen oxide (NO^x) species react with oxygen-derived radicals, redox metals, and thiols (Figure 3) (156-157). Nitric oxide can be reduced to nitrous oxide (N_2O) or oxidized to nitrite (NO_2^-) (157). Nitrite can react rapidly with oxygen, yielding nitrogen dioxide radical ($^\bullet\text{NO}_2$), which exists in equilibrium with the potent nitrosating agents dinitrogen trioxide (N_2O_3) and dinitrogen tetroxide (N_2O_4); $^\bullet\text{NO}_2$ can either react with unsaturated lipids directly or participate in nitrosation reactions. Nitric oxide does not directly nitrosate organic molecules without a strong oxidizing cofactor to accept an electron, such as transition metals or $^\bullet\text{NO}_2$. Dinitrogen trioxide can nitrosate cysteinyl residues (*S*-nitrosation), forming *S*-nitrosothiols (RSNO), which are naturally found in cells and plasma (158). Owing to their relative stability, *S*-nitrosothiols are an important form of NO and may serve as a functional storage pool of bioavailable NO (73). In plasma, *S*-nitrosoalbumin is an important NO adduct that may protect NO from inactivation in the oxidative extracellular milieu (158).

The dinitrogen species can also nitrosate (*N*-nitrosation) secondary amines to yield procarcinogenic *N*-nitrosamines (RNNO), and are involved in the formation of nitrotyrosine and *N*-nitrosotryptophan (159-161). These reactive nitrogen compounds can also nitrosatively deaminate deoxynucleosides and deoxynucleotides and promote mutagenic DNA strand breaks (162). Biochemical studies in rat aortas reveal that *N*-nitroso compounds also exist in vascular tissue, but functional data suggest that RSNOs are more active by an order of magnitude than RNNO (163). Additional studies are necessary to understand the biological significance of various RSNO and RNNO species.

At low concentrations, intracellular NO may function as an antioxidant through termination reactions with lipid radicals ($\text{L}^\bullet$, $\text{LO}^\bullet$, $\text{LOO}^\bullet$), resulting in the formation of less reactive secondary nitrogen-containing products (LONO, LOONO) at near diffusion-limited rates (10^9 to $10^{11} \text{ M}^{-1} \text{ s}^{-1}$) (142). LOONO can either decompose to caged radicals ($\text{LO}^\bullet \text{ } ^\bullet\text{NO}_2$) with rearrangement of $\text{LO}^\bullet$ to an epoxide ($\text{L}(\text{O})\text{NO}_2$), dissociate and react with additional NO, or hydrolyze to LOOH and nitrite (NO_2^-) (157). Thus, by these chemical actions, NO suppresses the generation of lipid-derived products that are chemotactic for monocytes, and can thereby be considered antiinflammatory and potentially antiatherosclerotic (164,165).

5.2.2. Nitric oxide signaling properties—Other antiatherosclerotic actions of NO are its antithrombotic antiplatelet effects that contribute to maintaining vascular integrity and blood

flow (166,167). Produced by the intact endothelium, potent platelet inhibitors include prostacyclin, endothelial surface-bound ecto-AD(T)Pase (CD39), and NO, all of which affect platelet activation and function in differing, but complementary, ways (168). Nitric oxide diffuses into platelets and, similar to effects on vascular smooth muscle cells, stimulates cGMP production and activates cGMP-dependent protein kinases, resulting in a decrease in intracellular Ca^{2+} flux (169-171). Ca^{2+} is also an important second messenger in platelets, and its accumulation leads to the phosphorylation and activation of several Ca^{2+} -dependent enzymes that results in cytoskeletal rearrangement, shape change, release of storage granules, and platelet aggregation (168). Furthermore, cGMP, in part through the downregulation of PKC, regulates the desensitization of the thromboxane A_2 (TXA_2) receptor, a potent stimulator of platelet aggregation and vasoconstriction. By attenuating conformational changes in glycoprotein (GP) IIb/IIIa, cGMP controls the number and affinity of fibrinogen binding sites on the platelet surface and prevents the surface expression of the alpha-granule protein P-selectin, a mediator of platelet adhesion (172,173). Nitric oxide may also inhibit platelet activation by cGMP-independent mechanisms, such as its effects on non-specific cation channels (169).

In addition, through cGMP-dependent and -independent mechanisms, NO participates in the regulation of vascular smooth muscle cell migration, growth, and proliferation. Calcium promotes vascular smooth muscle cell proliferation, and, as in other cell types, NO decreases intracellular Ca^{2+} flux mediated by cGMP, promoting its antiproliferative action (174). In addition to regulating platelet and vascular smooth muscle cell function, NO has anti-inflammatory effects by controlling leukocyte responses through inhibition of cytokine-mediated cell adhesion molecule expression (175,176).

6. ATHEROTHROMBOSIS

6.1. Impaired vascular nitric oxide bioavailability and oxidative stress

A dominant mechanisms of impaired vascular NO bioavailability relates to its oxidative inactivation by $\text{O}_2^{\bullet-}$. A central feature of impaired endothelial function is the presence of ROS manifested by ox-LDL in hypercholesterolemia, glycoxidation products in hyperglycemia, redox-active compounds in tobacco smoke, and lipid peroxides in hyperhomocysteinemia owing to the homocysteine-dependent suppression of GPx-1 (177-179). Oxidized lipids can also be generated by metal-dependent Fenton oxidation; enzyme-catalyzed oxidation by lipoxygenase (LOX) (180-182) or reaction with HOCl generated by myeloperoxidase; cell-dependent oxidation via a diversity of $\text{O}_2^{\bullet-}$ and H_2O_2 -generating oxidases; and oxidation by NO-derived reactive nitrogen species such as $\text{NO}_2^{\bullet}$, nitryl chloride (NO_2Cl), and peroxynitrite (183-185).

Oxidative stress, particularly ox-LDL, plays a key role at several steps of atherogenesis, according to the 'oxidative-modification hypothesis of atherosclerosis' (186-188). Initially localized in the vascular subendothelial space, LDL is oxidatively modified by endothelial cells, vascular smooth muscle cells, and monocytes. Macrophages within the vessel wall internalize ox-LDL via scavenger receptors, and develop into lipid-rich 'foam cells' (189-191). Evidence that LDL oxidation occurs *in vivo* is supported by the reaction of ox-LDL antibodies with atherosclerotic lesions (188,192).

6.2. Inflammation

Oxidation of LDL and increased oxidative stress stimulates proinflammatory signals by transcription of genes sensitive to changes in cellular oxidant production, as well as by modulation of cell-signaling events (193). Following exposure to cytokines, such as interleukin-1 β or TNF- α , endothelial cells are activated to express vascular cell adhesion

molecule-1, intercellular adhesion molecule-1, and E-selectin, all of which promote leukocyte binding. Moreover, the activated endothelium produces chemoattractants, such as interleukin-8 and monocyte chemoattractant protein-1, that facilitate monocyte recruitment and adhesion to the vessel wall and initiate early stages of atherosclerosis (194,195). Superoxide anion and other ROS also promote transcription-dependent inflammatory processes, in part, controlled by the redox-sensitive transcriptional regulatory protein NFkappaB that is normally downregulated by NO under physiological conditions (196). NFkappaB is also important in proliferative signals involved in vascular smooth muscle cell growth, vascular remodeling, and atherogenesis. Evidence for the involvement of ROS in NFkappaB activation is provided by studies demonstrating its downregulation by antioxidants, such as catalase, SOD, and *N*-acetylcysteine (84).

The role of ROS in inflammation is supported by the fact that NAD(P)H oxidase-dependent $O_2^{\bullet-}$ production is found in shoulder regions of the atherosclerotic plaque (34). In this region, ROS also correlate with an increase in the proteolytic activity of matrix metalloproteinases (197,198). In patients with acute coronary syndrome, atherectomy specimens show increased levels of ROS compared to those from patients with stable angina, supporting a mechanistic role for ROS in plaque composition and behavior (199). In hypercholesteremic rabbits, *N*-acetylcysteine, a potent antioxidant, decreases matrix metalloproteinases-9 expression and activation, suggesting antioxidant therapy may be an effective means to stabilize plaques (197). In the same animal model, $O_2^{\bullet-}$ is increased in aortic tissue, and treatment with SOD attenuates impairment of endothelium-dependent relaxation (5,200-201). Similarly, increased $O_2^{\bullet-}$ production is found in blood vessels from human subjects with coronary artery disease, hypercholesterolemia, and diabetes mellitus (202).

6.3. Peroxynitrite formation

In the atherosclerotic plaque, levels of NO can be elevated, generated typically after induction of iNOS (203). Exogenous cigarette smoke also yields high levels of NO that contribute to the formation of more potent secondary oxidants from $O_2^{\bullet-}$, most notably peroxynitrite (204). The formation of peroxynitrite from $O_2^{\bullet-}$ and NO occurs at the diffusion limit with a rate ($k \sim 6.7 \times 10^9 \text{ M}^{-1} \cdot \text{s}^{-1}$) (120,205) that is faster than that of the SOD reaction or of NO with heme compounds (206). Thus, NO can be considered a scavenger of $O_2^{\bullet-}$, even to the extent of acting as an antioxidant; in fact, NO is the only biological molecule that can kinetically outcompete SOD for $O_2^{\bullet-}$ (85,207-209). In mitochondria, NO binds to cytochrome oxidase, inhibits mitochondrial respiration, increases $O_2^{\bullet-}$ production, and potentially augments peroxynitrite formation (210,211). Significantly, peroxynitrite inactivates Mn-SOD, thereby increasing the flux of $O_2^{\bullet-}$ available to react with NO and establishing an autocatalytic spiral of increasing mitochondrial peroxynitrite formation (212,213).

At physiological pH, peroxynitrite exists primarily as peroxynitrite anion ($ONOO^-$), a stable base (pK_a of ~ 6.8 at 37°C) in *cis*-conformation. Its conjugate, peroxynitrous acid ($ONOOH$), comprises approximately 20% of total peroxynitrite at physiological pH. The *trans*-peroxynitrous acid is a strong oxidant and highly reactive, and, theoretically, may form an excited state that reacts like hydroxyl radical. Peroxynitrous acid is also capable of rearranging to nitrate (214,215). Peroxynitrite, unlike its precursor NO, is probably not an intercellular messenger molecule, although by modifying target proteins involved in signal transduction, peroxynitrite may have profound effects on cell signaling (216-217). Homolytic cleavage of peroxynitrite can produce $\bullet\text{OH}$ and $\bullet\text{NO}_2$, (205) which react together to form nitrate, to reform $HOONO$ (cage return), or diffuse apart, leaving free radicals that can cause other oxidative events.

Peroxynitrite formation has two important biological consequences: loss of bioactive NO and direct cytotoxic effects (Figure 4). Peroxynitrite and its conjugate acid can oxidize a variety of

biomolecules, including free thiols, such as cysteine, glutathione, or cysteinyl residues in protein; lipids; deoxyribose; guanine bases; methionine; and phenols (214,215,218-222). The consequences of these oxidations are protein modification, inhibition of mitochondrial respiration and of other enzymes, and lipid peroxidation (223). Peroxynitrite can also inactivate various ion channels, inhibit membrane Na^+/K^+ ATP-ase activity, and inactivate glyceraldehyde-3-phosphate dehydrogenase (224-226). The reaction with DNA to form 8-hydroxydeoxyguanosine, single DNA strand breaks, and the activation of the DNA repair nuclear enzyme poly-ADP ribosyl synthetase with depletion of cellular NADH are also important cytotoxic effects of peroxynitrite (221,227-229).

In the intracellular compartment, peroxynitrite may preferentially oxidize free thiols (RSH) such as glutathione in a second order reaction, particularly with the anion form (RS^-), resulting in the formation of an intermediate sulfenic acid (RSOH), that then reacts with another thiol, forming disulfides (RSSR) (214,230-231). Thiols may also be oxidized by the radicals formed from peroxynitrite, generating thiyl radicals ($\text{RS}^\bullet$); thiyl radicals may react with oxygen and promote oxidative stress or react with NO to form RSNO and promote transnitrosation of protein thiols (Protein-SNO). Peroxynitrite itself is not a direct nitrosating agent, but is involved in the nitrosation of thiols to yield RSNO or organic nitrates (RONO_2) (232-236). Peroxynitrite catalysis can be promoted by the presence of transition metals, SOD, or myeloperoxidase to produce hydroxyl anion (OH^-) plus nitronium cation (NO_2^+) (one-electron oxidation); NO_2^+ then reacts with phenolics to produce nitrophenols (237-238). The nitration of protein tyrosinyl residues to yield 3-nitrotyrosine is a stable byproduct left by the short-lived peroxynitrite *in vivo* (234). Tyrosine does not react directly with peroxynitrite; rather, tyrosine nitration occurs through a radical mechanisms in which a hydrogen atom is first abstracted from the phenol ring to form a tyrosyl radical that quickly combines with $^\bullet\text{NO}_2$ to produce 3-nitrotyrosine. This reaction competes favorably with a secondary reaction in which tyrosyl combines with another tyrosyl radical to form dityrosine (239,240). Immunodetectable 3-nitrotyrosine has been demonstrated in fatty streaks of coronary arteries of young autopsy subjects and in foam cells, vascular endothelium, and the neointima of advanced atherosclerotic lesions in older patients (241). Tyrosine nitration can inactivate enzymes (e.g., MnSOD) and disrupt tyrosine kinase signaling pathways by blocking tyrosine phosphorylation (212,242-243).

The plasma thiol concentration is approximately one-tenth that of the cytosol; therefore, extracellular peroxynitrite will tend to react with non-thiol targets, such as LDL, to generate vasoconstrictive isoprostanes and reactive aldehydes (244). Peroxynitrite is unique as a lipid oxidant, producing lipid peroxy radicals, and mediates peroxidation of diverse classes of lipids (e.g., purified fatty acids, neutral lipids, phospholipids, lipophilic antioxidants, and LDL lipids) forming conjugated dienes, malondialdehyde, lipid peroxides, lipid hydroxides, F_2 -isoprostanes, and oxysterol products (219,245-247). Peroxynitrite can also react with extracellular carbohydrates.

Cellular damage by peroxynitrite is augmented by its reaction with carbon dioxide radical ($\text{CO}_2^\bullet$) and formation of highly reactive free radicals. The concentration of carbon dioxide (CO_2) in the plasma is high ($\sim 1.3 \text{ mM}$), which is maintained by equilibrium with HCO_3^- ($\sim 25 \text{ mM}$). Consequently, in plasma the reaction rate of peroxynitrite with CO_2 will be ~ 60 -fold greater than that with thiols (248-249). The result of this reaction is the formation of nitrosoperoxy carbonate anion ($\text{ONO}_2\text{CO}_2^-$) ($k_2 \sim 5 \times 10^4 \text{ M}^{-1} \cdot \text{s}^{-1}$ at 37°C), which subsequently rearranges to form nitrocarbonate (248). Theoretically, nitrocarbonate can undergo hydrolysis to form carbonate radical ($\text{CO}_3^\bullet$) and $^\bullet\text{NO}_2$ as a pair of caged radicals, which $\sim 66\%$ of the time recombine to CO_2 plus NO_3^- and $\sim 33\%$ of the time escape the solvent cage; it is these radicals that are believed to cause peroxynitrite-related cellular NO damage (250). Nitrocarbonate can also oxidize substrates via one- and two-electron transfers, and may

also nitrosate substrates. *In vitro* studies have shown that CO₂ enhances tyrosine nitration by peroxynitrite (251).

Several approaches can be used to prevent or repair peroxynitrite-induced cellular injury. One can decrease the production of NO with NOS inhibitors, or decrease O₂^{•-} formation by increasing SOD levels or by inhibiting xanthine and NAD(P)H oxidases. Other approaches depend on enhancing the reduction of peroxynitrite to NO₂⁻ or rearrangement to NO₃⁻ by using organoselenium compounds, metalloporphyrin derivatives, and peroxidases (252-255). Glutathione peroxidase-1, the most abundant selenocysteine-containing GPx, may play a role in the reduction of peroxynitrite (137). The relevance of this enzyme in protecting against oxidative stress has been demonstrated in cell culture, murine models of GPx-1 deficiency, and human subjects (179,256-257). Compared to wild-type mice, heterozygous and homozygous GPx-1-deficient mice show an increase in plasma and aortic levels of isoprostane iPF_{2α}-III, a marker of oxidant stress. These GPx-1 deficient mice also have endothelial dysfunction and increased immunodetectable 3-nitrotyrosine in the aorta.

6.4. Platelet activation and thrombus formation

In response to blood vessel injury, platelets accumulate at the site, recruit other platelets, promote clotting, and form a hemostatic plug to prevent hemorrhage; in the course of their activation, platelets are a rich source of ROS, including O₂^{•-}, H₂O₂ and LOOH. In addition to promoting endothelial dysfunction and atherogenesis, NO insufficiency combined with ROS accumulation predisposes to a platelet-dependent prothrombotic disorder. Reduction of NO and induction of O₂^{•-} formation cause an increase in intracellular Ca²⁺ levels in platelets. Increased Ca²⁺ levels activate cytoskeletal rearrangement, alpha- and dense-granule release, and overall platelet activation. Impaired NO bioavailability causes secretion of TXA₂ from the platelets, which consequently activates additional platelets in the microenvironment of the platelet plug. For hemostatic plug formation, platelets interact with one another by forming crosslinks through cell surface integrin receptors, thereby leading to aggregation. Fibrinogen, a bivalent molecule, augments aggregation by linking the GPIIb/IIIa receptors between activated platelets (258). Nitric oxide released from activated platelets regulates the recruitment of additional platelets to the growing thrombus (259). Platelet adherence to the endothelium requires the expression of P-selectin, a cell-surface protein found in endothelial cells and alpha-granules of platelets, which is normally downregulated by NO (173,260). In a study of platelet function from human subjects with a thrombotic disorder, NO failed to inhibit platelet P-selectin expression and platelet aggregation. The unresponsiveness of these platelets to NO was found to be associated with decreased GPx-3 activity (261). Glutathione peroxidase-3 is the only isoform in the GPx family that is found in the extracellular space, and is responsible for the majority of the peroxidase activity in plasmas (262). Addition of exogenous GPx led to the restoration of NO's inhibitory effect on platelets in these patients' plasmas. Thus, GPx-3 maintains the bioavailability of NO by preventing the accumulation of ROS that are generated during the activation of the platelet second messenger cascade and may regulate subsequent conformational changes in cytoskeletal structure. In fact, H₂O₂ has been found to mediate changes in intracellular Ca²⁺ levels and affect Ca²⁺-related mechanisms through sulfhydryl oxidation-dependent and -independent mechanisms within platelets (263). The modulation of intracellular Ca²⁺ levels by H₂O₂ occurs through stimulatory Ca²⁺ release from the dense tubular system and mitochondria within platelets, concurrent with inhibition of Ca²⁺ reuptake into the dense tubular system mediated by sarcoplasmic reticulum Ca²⁺ ATPase (264,265). The consequences of platelet activation and thrombus formation, as well as atherosclerotic plaque disruption (rupture or erosion), are key features of atherothrombosis.

7. CONCLUSION

Cardiovascular risk factors promotes the production of ROS, and an imbalance between endogenous oxidants and antioxidants results in oxidative stress, a condition that contributes to impaired NO bioavailability and vascular dysfunction. The generation of $O_2^{\bullet-}$ by NAD(P)H oxidase in vascular smooth muscle cells and by NAD(P)H oxidase or uncoupled eNOS in activated or dysfunctional endothelial cells can promote the production of peroxynitrite from the diffusion-controlled reaction between $O_2^{\bullet-}$ and NO. Oxidative stress characterized by lipid and protein oxidation in the vascular wall is considered an early event in atherogenesis. The oxidative respiratory burst from leukocytes that enter the vessel wall in the early inflammatory response to vascular injury and the production of oxidized arachidonate derivatives by activated platelets in the early thrombotic response to vascular injury represent key mechanistic determinants of atherothrombosis that reflect ROS flux.

ACKNOWLEDGMENTS

This work was supported by NIH grants HL 58976, HL 61795, HV 28178, and HL 81587 from the National Heart, Lung, and Blood Institute (NHLBI), and by a Deutsche Forschungsgemeinschaft grant, LU 1452/1-1. The authors wish to thank Stephanie Tribuna for expert technical assistance, and Jutta Benirschke for graphics work.

Disclaimer: The project described was supported by Award numbers HL 61795, HL 58976, N01 HV 28178, and P01 HL 81587 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.

Abbreviations

AP-1, Activator protein-1
 ACE, angiotensin converting enzyme
 ADMA, asymmetric dimethyl arginine
 $CO_2^{\bullet}$, carbon dioxide radical
 CO_2 , carbon dioxide
 $CO_3^{\bullet-}$, carbonate radical
 cGMP, cyclic guanosine 3',5'-cyclic monophosphate
 FAD, flavin adenine nucleotide
 Fe^{2+} , ferron iron
 GSH, glutathione
 GSSG, glutathione disulfide
 GPx, glutathione peroxidase
 GP, glycoprotein
 HO, heme oxygenase isoform
 H_2O_2 , hydrogen peroxide
 OH^- , hydroxyl anion
 $\cdot OH$, hydroxyl radical
 HOCl, hypochlorous acid
 HIF-1, hypoxia-inducible factor-1
 LOX, lipoxygenase
 LDL, low density lipoprotein
 O_2 , molecular oxygen
 NAD(P)H, nicotinamide adenine dinucleotide (phosphate) oxidase
 NO_3^- , nitrate
 NO_2^- , nitrite
 NO, nitric oxide
 NOS, nitric oxide synthase

NO^{2+} , nitronium cation
 $\text{ONO}_2\text{CO}_2^-$, nitrosoperoxy carbonate
 NO_2Cl , nitryl chloride
 NANC, non-adrenergic, non-cholinergic
 Nox, non-phagocytic NAD(P)H oxidase
 N_2 , nitrogen
 NFkappaB, nuclear factor kappaB
 ROS, reactive oxygen species
 RNS, reactive nitrogen species
 RSOH, sulfenic acid
 $\text{O}_2^{\cdot-}$, superoxide anion
 SOD, superoxide dismutase
 ONOO^- , peroxynitrite anion
 ONOOH , peroxynitrous acid
 PKC, protein kinase C
 sGC, soluble guanylyl cyclase
 BH_4 , tetrahydrobiopterin
 TNF-alpha, tumor necrosis factor-alpha
 $\text{RS}^\bullet$, thiyl radical
 TXA_2 , thromboxane A_2
 XR, xanthine dehydrogenase
 XO, xanthine oxidase
 XOR, xanthine oxidoreductase
 H_2O , water

8. REFERENCES

1. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. *Cardiovasc Res* 1999;43:562–571. [PubMed: 10690328]
2. Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. *Am J Physiol* 1994;266:H2568–H2572. [PubMed: 8024019]
3. Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. *Microcirculation* 2002;9:161–175. [PubMed: 12080414]
4. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest* 1996;97:1916–1923. [PubMed: 8621776]
5. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore J, Freeman BA, et al. Superoxide and peroxynitrite in atherosclerosis. *Proc Natl Acad Sci U S A* 1994;91:1044–1048. [PubMed: 8302829]
6. Moncada S, Martin JF. Evolution of nitric oxide. *Lancet* 1993;341:1511. [PubMed: 8099386]
7. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. *Circ Res* 1990;66:1561–1575. [PubMed: 2160870]
8. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. *N Engl J Med* 1990;323:27–36. [PubMed: 2113184]
9. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. *Circulation* 2001;104:2673–2678. [PubMed: 11723017]

10. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. *Circulation* 2000;101:1899–1906. [PubMed: 10779454]
11. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. *Circ Res* 2000;87:840–844. [PubMed: 11073878]
12. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, Jones OT. Expression of phagocyte NADPH oxidase components in human endothelial cells. *Am J Physiol* 1996;271:H1626–H1634. [PubMed: 8897960]
13. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ Res* 1994;74:1141–1148. [PubMed: 8187280]
14. Sorescu D, Somers MJ, Lassegue B, Grant S, Harrison DG, Griendling KK. Electron spin resonance characterization of the NAD(P)H oxidase in vascular smooth muscle cells. *Free Radic Biol Med* 2001;30:603–612. [PubMed: 11295358]
15. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. *Proc Natl Acad Sci U S A* 1997;94:14483–14488. [PubMed: 9405639]
16. Pagano PJ, Chanock SJ, Siwik DA, Colucci WS, Clark JK. Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. *Hypertension* 1998;32:331–337. [PubMed: 9719063]
17. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. *Circ Res* 2000;86:494–501. [PubMed: 10720409]
18. Babior BM. NADPH oxidase: an update. *Blood* 1999;93:1464–1476. [PubMed: 10029572]
19. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD (P)H oxidase in human endothelial cells. *Biochem Biophys Res Commun* 2000;269:713–717. [PubMed: 10720482]
20. Holland JA, Pritchard KA, Pappolla MA, Wolin MS, Rogers NJ, Stemerman MB. Bradykinin induces superoxide anion release from human endothelial cells. *J Cell Physiol* 1990;143:21–25. [PubMed: 2156873]
21. Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, Alexander RW. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. *Circ Res* 2002;91:1160–1167. [PubMed: 12480817]
22. Matsubara T, Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. *J Immunol* 1986;137:3295–3298. [PubMed: 3021851]
23. Frey RS, Rahman A, Kefer JC, Minshall RD, Malik AB. PKCzeta regulates TNF-alpha-induced activation of NADPH oxidase in endothelial cells. *Circ Res* 2002;90:1012–1019. [PubMed: 12016268]
24. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. *Diabetes* 2000;49:1939–1945. [PubMed: 11078463]
25. Hwang J, Ing MH, Salazar A, Lassegue B, Griendling K, Navab M, Sevanian A, Hsiai TK. Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: implication for native LDL oxidation. *Circ Res* 2003;93:1225–1232. [PubMed: 14593003]
26. Lopes NH, Vasudevan SS, Gregg D, Selvakumar B, Pagano PJ, Kovacic H, Goldschmidt-Clermont PJ. Rac-dependent monocyte chemoattractant protein-1 production is induced by nutrient deprivation. *Circ Res* 2002;91:798–805. [PubMed: 12411394]
27. Kim KS, Takeda K, Sethi R, Pracyk JB, Tanaka K, Zhou YF, Yu ZX, Ferrans VJ, Bruder JT, Kovesdi I, Irani K, Goldschmidt-Clermont P, Finkel T. Protection from reoxygenation injury by inhibition of rac1. *J Clin Invest* 1998;101:1821–1826. [PubMed: 9576744]
28. Schinetti ML, Sbarbati R, Scarlattini M. Superoxide production by human umbilical vein endothelial cells in an anoxia-reoxygenation model. *Cardiovasc Res* 1989;23:76–80. [PubMed: 2550129]
29. Harrison DG. Endothelial function and oxidant stress. *Clin Cardiol* 1997;20:II-11–17.

30. Galle J, Heinloth A, Wanner C, Heermeier K. Dual effect of oxidized LDL on cell cycle in human endothelial cells through oxidative stress. *Kidney Int Suppl* 2001;78:S120–S123. [PubMed: 11168996]
31. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. *Circ Res* 2001;88:888–894. [PubMed: 11348997]
32. Banfi B, Molnar G, Maturana A, Steger K, Hegedus B, Demareux N, Krause KH. A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodes. *J Biol Chem* 2001;276:37594–37601. [PubMed: 11483596]
33. Gorlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. *Circ Res* 2000;87:26–32. [PubMed: 10884368]
34. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. *Circulation* 2002;105:1429–1435. [PubMed: 11914250]
35. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. *Circ Res* 2002;90:1205–1213. [PubMed: 12065324]
36. Rey FE, Li XC, Carretero OA, Garvin JL, Pagano PJ. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation: role of gp91(phox). *Circulation* 2002;106:2497–2502. [PubMed: 12417549]
37. Granger DN. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. *Am J Physiol* 1988;255:H1269–H1275. [PubMed: 3059826]
38. Cardillo C, Kilcoyne CM, Cannon RO 3rd, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. *Hypertension* 1997;30:57–63. [PubMed: 9231821]
39. Bouloumie A, Bauersachs J, Linz W, Scholkens BA, Wiemer G, Fleming I, Busse R. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. *Hypertension* 1997;30:934–941. [PubMed: 9336396]
40. Marletta MA. Nitric oxide synthase structure and mechanism. *J Biol Chem* 1993;268:12231–12234. [PubMed: 7685338]
41. Olken NM, Marletta MA. NG-methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase. *Biochemistry* 1993;32:9677–9685. [PubMed: 7690590]
42. Cosentino F, Katusic ZS. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. *Circulation* 1995;91:139–144. [PubMed: 7528647]
43. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukui T, Harrison DG. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. *Circulation* 2001;103:1282–1288. [PubMed: 11238274]
44. Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. *J Am Coll Cardiol* 2000;35:71–75. [PubMed: 10636262]
45. Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, Chayama K. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. *Am J Hypertens* 2002;15:326–332. [PubMed: 11991218]
46. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. *J Clin Invest* 1997;99:41–46. [PubMed: 9011574]
47. Verbeuren TJ, Jordaens FH, Zonnekeyn LL, Van Hove CE, Coene MC, Herman AG. Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. *Circ Res* 1986;58:552–564. [PubMed: 3486053]

48. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. *Circulation* 1990;81:491–497. [PubMed: 2105174]
49. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. *Circulation* 1993;88:2541–2547. [PubMed: 8252665]
50. Dhawan V, Handu SS, Nain CK, Ganguly NK. Chronic L-arginine supplementation improves endothelial cell vasoactive functions in hypercholesterolemic and atherosclerotic monkeys. *Mol Cell Biochem* 2005;269:1–11. [PubMed: 15786711]
51. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. *J Clin Invest* 1992;90:1168–1172. [PubMed: 1522225]
52. Wennmalm A, Edlund A, Granstrom EF, Wiklund O. Acute supplementation with the nitric oxide precursor L-arginine does not improve cardiovascular performance in patients with hypercholesterolemia. *Atherosclerosis* 1995;118:223–231. [PubMed: 8770316]
53. Bode-Boger SM, Scalera F, Ignarro LJ. The l-arginine paradox: Importance of the l-arginine/asymmetrical dimethylarginine ratio. *Pharmacol Ther* 2007;114:295–306. [PubMed: 17482266]
54. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. *J Clin Invest* 2002;109:817–826. [PubMed: 11901190]
55. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. *J Cardiovasc Pharmacol* 1992;20(Suppl 12):S60–S62. [PubMed: 1282988]
56. Boger RH, Vallance P, Cooke JP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. *Atheroscler Suppl* 2003;4:1–3. [PubMed: 14664896]
57. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. *Circulation* 1998;98:1842–1847. [PubMed: 9799202]
58. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Munzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. *Circ Res* 2005;97:e53–E59. [PubMed: 16100045]
59. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, Busse R. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. *Circ Res* 2001;88:44–51. [PubMed: 11139472]
60. Kukreja RC, Kontos HA, Hess ML, Ellis EF. PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH. *Circ Res* 1986;59:612–619. [PubMed: 3028671]
61. Boveris A. Mitochondrial production of superoxide radical and hydrogen peroxide. *Adv Exp Med Biol* 1977;78:67–82. [PubMed: 197811]
62. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. *Proc Natl Acad Sci USA* 1994;91:10771–10778. [PubMed: 7971961]
63. Archer SL, Weir EK, Reeve HL, Michelakis E. Molecular identification of O₂ sensors and O₂-sensitive potassium channels in the pulmonary circulation. *Adv Exp Med Biol* 2000;475:219–240. [PubMed: 10849663]
64. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. *Proc Natl Acad Sci USA* 2000;97:12222–12226. [PubMed: 11050244]
65. Pearlstein DP, Ali MH, Mungai PT, Hynes KL, Gewertz BL, Schumacker PT. Role of mitochondrial oxidant generation in endothelial cell responses to hypoxia. *Arterioscler Thromb Vasc Biol* 2002;22:566–573. [PubMed: 11950692]
66. Fridovich I. Superoxide radical: an endogenous toxicant. *Annu Rev Pharmacol Toxicol* 1983;23:239–257. [PubMed: 6307121]
67. Fridovich I. Biological effects of the superoxide radical. *Arch Biochem Biophys* 1986;247:1–11. [PubMed: 3010872]

68. Wolin MS, Burke-Wolin TM, Mohazzab HK. Roles for NAD(P)H oxidases and reactive oxygen species in vascular oxygen sensing mechanisms. *Respir Physiol* 1999;115:229–238. [PubMed: 10385036]
69. Halliwell B. Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. *Br J Exp Pathol* 1989;70:737–757. [PubMed: 2557883]
70. Kanner J, Harel S, Granit R. Nitric oxide as an antioxidant. *Arch Biochem Biophys* 1991;289:130–136. [PubMed: 1654842]
71. Marshall JJ, Kontos HA. Endothelium-derived relaxing factors. A perspective from *in vivo* data. *Hypertension* 1990;16:371–386. [PubMed: 2170274]
72. Rubanyi GM, Vanhoutte PM. Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle. *Am J Physiol* 1986;250:H815–H821. [PubMed: 3085520]
73. Rassaf T, Kleinbongard P, Preik M, Dejam A, Gharini P, Lauer T, Erckenbrecht J, Duschin A, Schulz R, Heusch G, Feelisch M, Kelm M. Plasma nitrosothiols contribute to the systemic vasodilator effects of intravenously applied NO: experimental and clinical Study on the fate of NO in human blood. *Circ Res* 2002;91:470–477. [PubMed: 12242264]
74. Grubina R, Huang Z, Shiva S, Joshi MS, Azarov I, Basu S, Ringwood LA, Jiang A, Hogg N, Kim-Shapiro DB, Gladwin MT. Concerted nitric oxide formation and release from the simultaneous reactions of nitrite with deoxy- and oxyhemoglobin. *J Biol Chem* 2007;282:12916–12927. [PubMed: 17322300]
75. Zweier JL, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. *Nat Med* 1995;1:804–809. [PubMed: 7585184]
76. Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Contractions to oxygen-derived free radicals are augmented in aorta of the spontaneously hypertensive rat. *Hypertension* 1989;13:859–864. [PubMed: 2567706]
77. Katusic ZS, Schugel J, Cosentino F, Vanhoutte PM. Endothelium-dependent contractions to oxygen-derived free radicals in the canine basilar artery. *Am J Physiol* 1993;264:H859–H864. [PubMed: 8456988]
78. Goodwin DC, Rowlinson SW, Marnett LJ. Substitution of tyrosine for the proximal histidine ligand to the heme of prostaglandin endoperoxide synthase 2: implications for the mechanism of cyclooxygenase activation and catalysis. *Biochemistry* 2000;39:5422–5432. [PubMed: 10820014]
79. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. *Free Radic Biol Med* 1994;16:383–391. [PubMed: 8063201]
80. Tesfamariam B, Cohen RA. Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. *Am J Physiol* 1992;262:H1915–H1919. [PubMed: 1320340]
81. Sorescu D, Szocs K, Griendling KK. NAD(P)H oxidases and their relevance to atherosclerosis. *Trends Cardiovasc Med* 2001;11:124–131. [PubMed: 11686001]
82. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. *Circulation* 1996;94:258–265. [PubMed: 8759064]
83. Munzel T, Keaney JF Jr. Are ACE inhibitors a “magic bullet” against oxidative stress? *Circulation* 2001;104:1571–1574. [PubMed: 11571254]
84. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. *Circ Res* 1999;85:753–766. [PubMed: 10521248]
85. Wolin MS. Interactions of oxidants with vascular signaling systems. *Arterioscler Thromb Vasc Biol* 2000;20:1430–1442. [PubMed: 10845855]
86. Lounsbury KM, Hu Q, Ziegelstein RC. Calcium signaling and oxidant stress in the vasculature. *Free Radic Biol Med* 2000;28:1362–1369. [PubMed: 10924855]
87. Suzuki YJ, Packer L, Ford GD. Relationships between the effects of superoxide anion and palmitoyl-L-carnitine on the Ca(2+)-ATPase of vascular smooth muscle sarcoplasmic reticulum. *J Mol Cell Cardiol* 1993;25:823–827. [PubMed: 8230244]

88. Iesaki T, Wolin MS. Thiol oxidation activates a novel redox-regulated coronary vasodilator mechanism involving inhibition of Ca²⁺ influx. *Arterioscler Thromb Vasc Biol* 2000;20:2359–2365. [PubMed: 11073838]
89. Zhong J, Hume JR, Keef KD. beta-Adrenergic receptor stimulation of L-type Ca²⁺ channels in rabbit portal vein myocytes involves both alphas and betagamma G protein subunits. *J Physiol* 2001;531:105–115. [PubMed: 11179395]
90. Kooy NW, Royall JA. Agonist-induced peroxynitrite production from endothelial cells. *Arch Biochem Biophys* 1994;310:352–359. [PubMed: 8179319]
91. Liu Y, Terata K, Rusch NJ, Gutterman DD. High glucose impairs voltage-gated K(+) channel current in rat small coronary arteries. *Circ Res* 2001;89:146–152. [PubMed: 11463721]
92. Tokube K, Kiyosue T, Arita M. Effects of hydroxyl radicals on KATP channels in guinea-pig ventricular myocytes. *Pflugers Arch* 1998;437:155–157. [PubMed: 9817800]
93. Mukhopadhyay CK, Fox PL. Ceruloplasmin copper induces oxidant damage by a redox process utilizing cell-derived superoxide as reductant. *Biochemistry* 1998;37:14222–14229. [PubMed: 9760260]
94. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. *Free Radic Biol Med* 2000;28:1717–1725. [PubMed: 10946213]
95. Jin N, Rhoades RA. Activation of tyrosine kinases in H₂O₂-induced contraction in pulmonary artery. *Am J Physiol* 1997;272:H2686–H2692. [PubMed: 9227547]
96. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H₂O₂ for platelet-derived growth factor signal transduction. *Science* 1995;270:296–299. [PubMed: 7569979]
97. Davies KJ. Oxidative stress: the paradox of aerobic life. *Biochem Soc Symp* 1995;61:1–31. [PubMed: 8660387]
98. Vertuani S, Angusti A, Manfredini S. The antioxidants and pro-antioxidants network: an overview. *Curr Pharm Des* 2004;10:1677–1694. [PubMed: 15134565]
99. Sies H. Oxidative stress: oxidants and antioxidants. *Exp Physiol* 1997;82:291–295. [PubMed: 9129943]
100. Wells WW, Xu DP, Yang YF, Rocque PA. Mammalian thioltransferase (glutaredoxin) and protein disulfide isomerase have dehydroascorbate reductase activity. *J Biol Chem* 1990;265:15361–15364. [PubMed: 2394726]
101. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, Chen S, Corpe C, Dutta A, Dutta SK, Levine M. Vitamin C as an antioxidant: evaluation of its role in disease prevention. *J Am Coll Nutr* 2003;22:18–35. [PubMed: 12569111]
102. Carr A, Frei B. Does vitamin C act as a pro-oxidant under physiological conditions? *FASEB J* 1999;13:1007–1024. [PubMed: 10336883]
103. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. *Circulation* 1998;97:2222–2229. [PubMed: 9631871]
104. Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. *Circulation* 1997;95:2617–2622. [PubMed: 9193429]
105. Herrera E, Barbas C. Vitamin E: action, metabolism and perspectives. *J Physiol Biochem* 2001;57:43–56.
106. Brigelius-Flohe R, Traber MG. Vitamin E: function and metabolism. *FASEB J* 1999;13:1145–1155. [PubMed: 10385606]
107. Wang X, Quinn PJ. Vitamin E and its function in membranes. *Prog Lipid Res* 1999;38:309–336. [PubMed: 10793887]
108. Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. *Life Sci* 2006;78:2088–2098. [PubMed: 16458936]
109. Zingg JM. Modulation of signal transduction by vitamin E. *Mol Aspects Med* Oct-Dec;2007 28(56): 400–22. [PubMed: 17624418]Epub 2007 Jun 2

110. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). *Lancet* 1996;347:781–786. [PubMed: 8622332]
111. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342:154–160. [PubMed: 10639540]
112. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 2001;345:1583–1592. [PubMed: 11757504]
113. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. *JAMA* 2005;293:1338–1347. [PubMed: 15769967]
114. Meister A, Anderson ME. Glutathione. *Annu Rev Biochem* 1983;52:711–760. [PubMed: 6137189]
115. Meister A. Glutathione metabolism and its selective modification. *J Biol Chem* 1988;263:17205–17208. [PubMed: 3053703]
116. Meister A. Glutathione-ascorbic acid antioxidant system in animals. *J Biol Chem* 1994;269:9397–9400. [PubMed: 8144521]
117. Ma XL, Lopez BL, Liu GL, Christopher TA, Gao F, Guo Y, Feuerstein GZ, Ruffolo RR Jr, Barone FC, Yue TL. Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury. *Circ Res* 1997;80:894–901. [PubMed: 9168793]
118. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. *Am J Physiol* 1986;250:H822–H827. [PubMed: 3010744]
119. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. *Nature* 1986;320:454–456. [PubMed: 3007998]
120. Goldstein S, Czapski G. The reaction of NO. with O₂.– and HO₂.: a pulse radiolysis study. *Free Radic Biol Med* 1995;19:505–510. [PubMed: 7590401]
121. Gow AJ, Ischiropoulos H. Nitric oxide chemistry and cellular signaling. *J Cell Physiol* 2001;187:277–282. [PubMed: 11319751]
122. Sampson JB, Beckman JS. Hydrogen peroxide damages the zinc-binding site of zinc-deficient Cu,Zn superoxide dismutase. *Arch Biochem Biophys* 2001;392:8–13. [PubMed: 11469788]
123. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. *N Engl J Med* 2001;344:1688–1700. [PubMed: 11386269]
124. Brown GC. Nitric oxide and mitochondrial respiration. *Biochim Biophys Acta* 1999;1411:351–369. [PubMed: 10320668]
125. Inoue N, Ramasamy S, Fukai T, Nerem RM, Harrison DG. Shear stress modulates expression of Cu/Zn superoxide dismutase in human aortic endothelial cells. *Circ Res* 1996;79:32–37. [PubMed: 8925565]
126. Stralin P, Karlsson K, Johansson BO, Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. *Arterioscler Thromb Vasc Biol* 1995;15:2032–2036. [PubMed: 7583586]
127. Chelikani P, Fita I, Loewen PC. Diversity of structures and properties among catalases. *Cell Mol Life Sci* 2004;61:192–208. [PubMed: 14745498]
128. del Rio LA, Sandalio LM, Palma JM, Bueno P, Corpas FJ. Metabolism of oxygen radicals in peroxisomes and cellular implications. *Free Radic Biol Med* 1992;13:557–580. [PubMed: 1334030]
129. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. *Free Radic Biol Med* 2005;38:1543–1552. [PubMed: 15917183]
130. Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. *Trends Biochem Sci* 2003;28:32–40. [PubMed: 12517450]
131. Claiborne A, Yeh JJ, Mallett TC, Luba J, Crane EJ 3rd, Charrier V, Parsonage D. Protein-sulfenic acids: diverse roles for an unlikely player in enzyme catalysis and redox regulation. *Biochemistry* 1999;38:15407–15416. [PubMed: 10569923]

132. Yamawaki H, Haendeler J, Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. *Circ Res* 2003;93:1029–1033. [PubMed: 14645133]
133. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. *Free Radic Biol Med* 2001;31:1287–312. [PubMed: 11728801]
134. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. *Eur J Biochem* 2000;267:6102–6109. [PubMed: 11012661]
135. Mustacich D, Powis G. Thioredoxin reductase. *Biochem J* 2000;346(Pt 1):1–8. [PubMed: 10657232]
136. Brigelius-Flohe R. Tissue-specific functions of individual glutathione peroxidases. *Free Radic Biol Med* 1999;27:951–965. [PubMed: 10569628]
137. Sies H, Sharov VS, Klotz LO, Briviba K. Glutathione peroxidase protects against peroxynitrite-mediated oxidations. A new function for selenoproteins as peroxynitrite reductase. *J Biol Chem* 1997;272:27812–27817. [PubMed: 9346926]
138. Sharma R, Yang Y, Sharma A, Awasthi S, Awasthi YC. Antioxidant role of glutathione S-transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis. *Antioxid Redox Signal* 2004;6:289–300. [PubMed: 15025930]
139. Perrella MA, Yet SF. Role of heme oxygenase-1 in cardiovascular function. *Curr Pharm Des* 2003;9:2479–2487. [PubMed: 14529547]
140. Murad F. Nitric oxide signaling: would you believe that a simple free radical could be a second messenger, autacoid, paracrine substance, neurotransmitter, and hormone? *Recent Prog Horm Res* 1998;53:43–59. [PubMed: 9769702]discussion 59-60
141. Hanafy KA, Krumenacker JS, Murad F. NO, nitrotyrosine, and cyclic GMP in signal transduction. *Med Sci Monit* 2001;7:801–819. [PubMed: 11433215]
142. Padmaja S, Huie RE. The reaction of nitric oxide with organic peroxy radicals. *Biochem Biophys Res Commun* 1993;195:539–544. [PubMed: 8373394]
143. Cleeter MW, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AH. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. *FEBS Lett* 1994;345:50–54. [PubMed: 8194600]
144. Eich RF, Li T, Lemon DD, Doherty DH, Curry SR, Aitken JF, Mathews AJ, Johnson KA, Smith RD, Phillips GN Jr, Olson JS. Mechanism of NO-induced oxidation of myoglobin and hemoglobin. *Biochemistry* 1996;35:6976–6983. [PubMed: 8679521]
145. Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. *Ann N Y Acad Sci* 1993;686:12–27. [PubMed: 8512242]discussion 27-28
146. Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical relevance. *Eur J Clin Invest* 1991;21:361–374. [PubMed: 1718757]
147. Lipton SA. Neuronal protection and destruction by NO. *Cell Death Differ* 1999;6:943–951. [PubMed: 10556970]
148. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries *in vivo*. *Circulation* 1995;91:1314–1319. [PubMed: 7867167]
149. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. *J Biol Chem* 1994;269:13725–13728. [PubMed: 7514592]
150. Stuehr DJ. Mammalian nitric oxide synthases. *Biochim Biophys Acta* 1999;1411:217–230. [PubMed: 10320659]
151. Wang Y, Newton DC, Marsden PA. Neuronal NOS: gene structure, mRNA diversity, and functional relevance. *Crit Rev Neurobiol* 1999;13:21–43. [PubMed: 10223522]
152. Doyle MP, Hoekstra JW. Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. *J Inorg Biochem* 1981;14:351–358. [PubMed: 7276933]
153. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. *Nature* 1994;368:850–853. [PubMed: 7512692]
154. Cohen RA, Weisbrod RM, Gericke M, Yaghoubi M, Bierl C, Bolotina VM. Mechanism of nitric oxide-induced vasodilatation: refilling of intracellular stores by sarcoplasmic reticulum Ca²⁺

- ATPase and inhibition of store-operated Ca^{2+} influx. *Circ Res* 1999;84:210–219. [PubMed: 9933253]
155. Horowitz A, Menice CB, Laporte R, Morgan KG. Mechanisms of smooth muscle contraction. *Physiol Rev* 1996;76:967–1003. [PubMed: 8874491]
 156. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. *Science* 1992;258:1898–1902. [PubMed: 1281928]
 157. Wink DA, Nims RW, Darbyshire JF, Christodoulou D, Hanbauer I, Cox GW, Laval F, Laval J, Cook JA, Krishna MC, et al. Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH. Insights into the fate and physiological effects of intermediates generated in the NO/O₂ reaction. *Chem Res Toxicol* 1994;7:519–525. [PubMed: 7981416]
 158. Stamler JS, Jaraki O, Osborne J, Simon DI, Keaney J, Vita J, Singel D, Valeri CR, Loscalzo J. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. *Proc Natl Acad Sci USA* 1992;89:7674–7677. [PubMed: 1502182]
 159. Challis BC, Edwards A, Hunma RR, Kyrtopoulos SA, Outram JR. Rapid formation of N-nitrosamines from nitrogen oxides under neutral and alkaline conditions. *IARC Sci Publ* 1978;19:127–42. [PubMed: 28274]
 160. Tannenbaum SR, Wishnok JS, Leaf CD. Inhibition of nitrosamine formation by ascorbic acid. *Am J Clin Nutr* 1991;53:247S–250S. [PubMed: 1985394]
 161. Zhang YY, Xu AM, Nomen M, Walsh M, Keaney JF Jr, Loscalzo J. Nitrosation of tryptophan residue (s) in serum albumin and model dipeptides. Biochemical characterization and bioactivity. *J Biol Chem* 1996;271:14271–14279. [PubMed: 8662958]
 162. Wink DA, Kasprzak KS, Maragos CM, Elespuru RK, Misra M, Dunams TM, Cebula TA, Koch WH, Andrews AW, Allen JS, et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. *Science* 1991;254:1001–1003. [PubMed: 1948068]
 163. Rodriguez J, Maloney RE, Rassaf T, Bryan NS, Feelisch M. Chemical nature of nitric oxide storage forms in rat vascular tissue. *Proc Natl Acad Sci USA* 2003;100:336–341. [PubMed: 12502793]
 164. Boger RH, Bode-Boger SM, Kienke S, Stan AC, Nafe R, Frolich JC. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. *Atherosclerosis* 1998;136:67–77. [PubMed: 9544733]
 165. Bult H. Nitric oxide and atherosclerosis: possible implications for therapy. *Mol Med Today* 1996;2:510–518. [PubMed: 9015792]
 166. Busse R, Luckhoff A, Bassege E. Endothelium-derived relaxant factor inhibits platelet activation. *Naunyn Schmiedebergs Arch Pharmacol* 1987;336:566–571. [PubMed: 2830546]
 167. Ware JA, Heistad DD. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. *N Engl J Med* 1993;328:628–635. [PubMed: 8429855]
 168. Battinelli E, Loscalzo J. Nitric oxide induces apoptosis in megakaryocytic cell lines. *Blood* 2000;95:3451–3459. [PubMed: 10828028]
 169. Trepakova ES, Cohen RA, Bolotina VM. Nitric oxide inhibits capacitative cation influx in human platelets by promoting sarcoplasmic/endoplasmic reticulum Ca^{2+} -ATPase-dependent refilling of Ca^{2+} stores. *Circ Res* 1999;84:201–209. [PubMed: 9933252]
 170. Moro MA, Russel RJ, Celtek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW, Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. *Proc Natl Acad Sci USA* 1996;93:1480–1485. [PubMed: 8643658]
 171. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. *Proc Natl Acad Sci USA* 1990;87:5193–5197. [PubMed: 1695013]
 172. Michelson AD, Benoit SE, Furman MI, Breckwoldt WL, Rohrer MJ, Barnard MR, Loscalzo J. Effects of nitric oxide/EDRF on platelet surface glycoproteins. *Am J Physiol* 1996;270:H1640–H1648. [PubMed: 8928869]
 173. Murohara T, Parkinson SJ, Waldman SA, Lefer AM. Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C. *Arterioscler Thromb Vasc Biol* 1995;15:2068–2075. [PubMed: 7583591]
 174. Walford G, Loscalzo J. Nitric oxide in vascular biology. *J Thromb Haemost* 2003;1:2112–2118. [PubMed: 14521592]

175. Bath PM, Hassall DG, Gladwin AM, Palmer RM, Martin JF. Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium *in vitro*. *Arterioscler Thromb* 1991;11:254–260. [PubMed: 1847823]
176. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr. Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. *J Clin Invest* 1995;96:60–68. [PubMed: 7542286]
177. Welch GN, Upchurch G Jr. Loscalzo J. Hyperhomocyst(e)inemia and atherothrombosis. *Ann N Y Acad Sci* 1997;811:48–58. [PubMed: 9186584]discussion 58-59
178. Welch GN, Upchurch GR Jr. Loscalzo J. Homocysteine, oxidative stress, and vascular disease. *Hosp Pract (Minneap)* 1997;32:81–82. [PubMed: 9194803]85, 88-92
179. Forgione MA, Weiss N, Heydrick S, Cap A, Klings ES, Bierl C, Eberhardt RT, Farber HW, Loscalzo J. Cellular glutathione peroxidase deficiency and endothelial dysfunction. *Am J Physiol Heart Circ Physiol* 2002;282:H1255–H1261. [PubMed: 11893559]
180. Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. *J Clin Invest* 1995;96:504–510. [PubMed: 7615823]
181. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. *J Clin Invest* 1999;103:1597–1604. [PubMed: 10359569]
182. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, Kuhn H, Guevara NV, Chan L. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. *J Clin Invest* 1996;98:2201–2208. [PubMed: 8941635]
183. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. *J Clin Invest* 1994;94:437–444. [PubMed: 8040285]
184. Sparrow CP, Parthasarathy S, Steinberg D. Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification. *J Lipid Res* 1988;29:745–753. [PubMed: 3139813]
185. Panasencko OM, Briviba K, Klotz LO, Sies H. Oxidative modification and nitration of human low-density lipoproteins by the reaction of hypochlorous acid with nitrite. *Arch Biochem Biophys* 1997;343:254–259. [PubMed: 9224738]
186. Witztum JL. The oxidation hypothesis of atherosclerosis. *Lancet* 1994;344:793–795. [PubMed: 7916078]
187. Westhuyzen J. The oxidation hypothesis of atherosclerosis: an update. *Ann Clin Lab Sci* 1997;27:1–10. [PubMed: 8997452]
188. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. *N Engl J Med* 1989;320:915–924. [PubMed: 2648148]
189. Graham A, Hogg N, Kalyanaraman B, O'Leary V, Darley-Usmar V, Moncada S. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. *FEBS Lett* 1993;330:181–185. [PubMed: 8365489]
190. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form *in vitro*. *J Clin Invest* 1999;103:1547–1560. [PubMed: 10359564]
191. Panasencko OM, Sharov VS, Briviba K, Sies H. Interaction of peroxynitrite with carotenoids in human low density lipoproteins. *Arch Biochem Biophys* 2000;373:302–305. [PubMed: 10620353]
192. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. *J Clin Invest* 1991;88:1785–1792. [PubMed: 1752940]
193. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, Griendling KK. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. *J Biol Chem* 1999;274:22699–22704. [PubMed: 10428852]
194. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, et al. Monocyte transmigration induced by modification of low density lipoprotein in

- cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. *J Clin Invest* 1991;88:2039–2046. [PubMed: 1752961]
195. Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. *Circulation* 1997;96:2361–2367. [PubMed: 9337212]
 196. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. *J Am Coll Cardiol* 2001;38:307–14. [PubMed: 11499717]
 197. Galis ZS, Asanuma K, Godin D, Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? *Circulation* 1998;97:2445–2453. [PubMed: 9641697]
 198. Channon KM. Oxidative stress and coronary plaque stability. *Arterioscler Thromb Vasc Biol* 2002;22:1751–1752. [PubMed: 12426198]
 199. Azumi H, Inoue N, Ohashi Y, Terashima M, Mori T, Fujita H, Awano K, Kobayashi K, Maeda K, Hata K, Shinke T, Kobayashi S, Hirata K, Kawashima S, Itabe H, Hayashi Y, Imajoh-Ohmi S, Itoh H, Yokoyama M. Superoxide generation in directional coronary atherectomy specimens of patients with angina pectoris: important role of NAD(P)H oxidase. *Arterioscler Thromb Vasc Biol* 2002;22:1838–1844. [PubMed: 12426213]
 200. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. *J Clin Invest* 1993;91:2546–2551. [PubMed: 8390482]
 201. Mugge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DG. Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. *Circ Res* 1991;69:1293–1300. [PubMed: 1934359]
 202. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. *Circ Res* 2000;86:E85–E90. [PubMed: 10807876]
 203. Bittery LD, Springall DR, Chester AH, Evans TJ, Standfield EN, Parums DV, Yacoub MH, Polak JM. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. *Lab Invest* 1996;75:77–85. [PubMed: 8683942]
 204. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci USA* 1990;87:1620–1624. [PubMed: 2154753]
 205. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. *Am J Physiol* 1995;268:L699–L722. [PubMed: 7762673]
 206. Traylor TG, Sharma VS. Why NO? *Biochemistry* 1992;31:2847–2849. [PubMed: 1348002]
 207. Gorren AC, de Boer E, Wever R. The reaction of nitric oxide with copper proteins and the photodissociation of copper-NO complexes. *Biochim Biophys Acta* 1987;916:38–47. [PubMed: 2822126]
 208. Rubbo H, Radi R, Trujillo M, Telleri R, Kalyanaraman B, Barnes S, Kirk M, Freeman BA. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. *J Biol Chem* 1994;269:26066–26075. [PubMed: 7929318]
 209. Wink DA, Hanbauer I, Krishna MC, DeGraff W, Gamson J, Mitchell JB. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. *Proc Natl Acad Sci USA* 1993;90:9813–9817. [PubMed: 8234317]
 210. Packer MA, Scarlett JL, Martin SW, Murphy MP. Induction of the mitochondrial permeability transition by peroxynitrite. *Biochem Soc Trans* 1997;25:909–914. [PubMed: 9388571]
 211. Poderoso JJ, Carreras MC, Lisdero C, Riobo N, Schopfer F, Boveris A. Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. *Arch Biochem Biophys* 1996;328:85–92. [PubMed: 8638942]
 212. MacMillan-Crow LA, Crow JP, Kerby JD, Beckman JS, Thompson JA. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. *Proc Natl Acad Sci USA* 1996;93:11853–8. [PubMed: 8876227]

213. Wolin MS, Hintze TH, Shen W, Mohazzab HK, Xie YW. Involvement of reactive oxygen and nitrogen species in signalling mechanisms that control tissue respiration in muscle. *Biochem Soc Trans* 1997;25:934–939. [PubMed: 9388576]
214. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. *J Biol Chem* 1991;266:4244–4250. [PubMed: 1847917]
215. Koppenol WH, Moreno JJ, Pryor WA, Ischiropoulos H, Beckman JS. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. *Chem Res Toxicol* 1992;5:834–842. [PubMed: 1336991]
216. Saran M, Bors W. Signalling by O₂^{•−} and NO[•]: how far can either radical, or any specific reaction product, transmit a message under *in vivo* conditions? *Chem Biol Interact* 1994;90:35–45. [PubMed: 8131218]
217. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev* 2007;87:315–424. [PubMed: 17237348]
218. Moreno JJ, Pryor WA. Inactivation of alpha 1-proteinase inhibitor by peroxynitrite. *Chem Res Toxicol* 1992;5:425–431. [PubMed: 1504267]
219. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. *Arch Biochem Biophys* 1991;288:481–487. [PubMed: 1654835]
220. Yermilov V, Rubio J, Ohshima H. Formation of 8-nitroguanine in DNA treated with peroxynitrite *in vitro* and its rapid removal from DNA by depurination. *FEBS Lett* 1995;376:207–210. [PubMed: 7498543]
221. Inoue S, Kawanishi S. Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide. *FEBS Lett* 1995;371:86–88. [PubMed: 7664890]
222. Quijano C, Alvarez B, Gatti RM, Augusto O, Radi R. Pathways of peroxynitrite oxidation of thiol groups. *Biochem J* 1997;322(Pt 1):167–173. [PubMed: 9078258]
223. Radi R, Bush KM, Cosgrove TP, Freeman BA. Reaction of xanthine oxidase-derived oxidants with lipid and protein of human plasma. *Arch Biochem Biophys* 1991;286:117–125. [PubMed: 1897941]
224. Hu P, Ischiropoulos H, Beckman JS, Matalon S. Peroxynitrite inhibition of oxygen consumption and sodium transport in alveolar type II cells. *Am J Physiol* 1994;266:L628–L634. [PubMed: 8023951]
225. Bauer ML, Beckman JS, Bridges RJ, Fuller CM, Matalon S. Peroxynitrite inhibits sodium uptake in rat colonic membrane vesicles. *Biochim Biophys Acta* 1992;1104:87–94. [PubMed: 1550856]
226. Ishida H, Ichimori K, Hirota Y, Fukahori M, Nakazawa H. Peroxynitrite-induced cardiac myocyte injury. *Free Radic Biol Med* 1996;20:343–350. [PubMed: 8720904]
227. Salgo MG, Stone K, Squadrito GL, Battista JR, Pryor WA. Peroxynitrite causes DNA nicks in plasmid pBR322. *Biochem Biophys Res Commun* 1995;210:1025–1030. [PubMed: 7763229]
228. Szabo C, Ohshima H. DNA damage induced by peroxynitrite: subsequent biological effects. *Nitric Oxide* 1997;1:373–385. [PubMed: 9441908]
229. Liu RH, Hotchkiss JH. Potential genotoxicity of chronically elevated nitric oxide: a review. *Mutat Res* 1995;339:73–89. [PubMed: 7791803]
230. Reed DJ. Glutathione: toxicological implications. *Annu Rev Pharmacol Toxicol* 1990;30:603–631. [PubMed: 2188580]
231. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. *Amino Acids* 2003;25:295–311. [PubMed: 14661092]
232. Ducrocq C, Blanchard B, Pignatelli B, Ohshima H. Peroxynitrite: an endogenous oxidizing and nitrating agent. *Cell Mol Life Sci* 1999;55:1068–1077. [PubMed: 10442088]
233. Wink DA, Darbyshire JF, Nims RW, Saavedra JE, Ford PC. Reactions of the bioregulatory agent nitric oxide in oxygenated aqueous media: determination of the kinetics for oxidation and nitrosation by intermediates generated in the NO/O₂ reaction. *Chem Res Toxicol* 1993;6:23–27. [PubMed: 8448345]
234. Beckman JS, Ischiropoulos H, Zhu L, van der Woerd M, Smith C, Chen J, Harrison J, Martin JC, Tsai M. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. *Arch Biochem Biophys* 1992;298:438–445. [PubMed: 1416975]

235. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, Loscalzo J, Singel DJ, Stamler JS. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. *Nature* 1993;364:626–632. [PubMed: 8394509]
236. Mayer B, Schrammel A, Klatt P, Koesling D, Schmidt K. Peroxynitrite-induced accumulation of cyclic GMP in endothelial cells and stimulation of purified soluble guanylyl cyclase. Dependence on glutathione and possible role of S-nitrosation. *J Biol Chem* 1995;270:17355–17360. [PubMed: 7615539]
237. Sampson JB, Rosen H, Beckman JS. Peroxynitrite-dependent tyrosine nitration catalyzed by superoxide dismutase, myeloperoxidase, and horseradish peroxidase. *Methods Enzymol* 1996;269:210–218. [PubMed: 8791651]
238. Pryor WA, Jin X, Squadrito GL. One- and two-electron oxidations of methionine by peroxynitrite. *Proc Natl Acad Sci USA* 1994;91:11173–11177. [PubMed: 7972029]
239. Ischiropoulos H. Biological selectivity and functional aspects of protein tyrosine nitration. *Biochem Biophys Res Commun* 2003;305:776–783. [PubMed: 12763060]
240. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. *Proc Natl Acad Sci USA* 2004;101:4003–4008. [PubMed: 15020765]
241. Beckman JS, Chen J, Ischiropoulos H, Crow JP. Oxidative chemistry of peroxynitrite. *Methods Enzymol* 1994;233:229–240. [PubMed: 8015460]
242. Kong LY, McMillian MK, Maronpot R, Hong JS. Protein tyrosine kinase inhibitors suppress the production of nitric oxide in mixed glia, microglia-enriched or astrocyte-enriched cultures. *Brain Res* 1996;729:102–109. [PubMed: 8874881]
243. Li X, De Sarno P, Song L, Beckman JS, Jope RS. Peroxynitrite modulates tyrosine phosphorylation and phosphoinositide signalling in human neuroblastoma SH-SY5Y cells: attenuated effects in human 1321N1 astrocytoma cells. *Biochem J* 1998;331(Pt 2):599–606. [PubMed: 9531503]
244. Ellman G, Lysko H. A precise method for the determination of whole blood and plasma sulfhydryl groups. *Anal Biochem* 1979;93:98–102. [PubMed: 434474]
245. Darley-Usmar VM, Hogg N, O'Leary VJ, Wilson MT, Moncada S. The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. *Free Radic Res Commun* 1992;17:9–20. [PubMed: 1332919]
246. Laskey RE, Mathews WR. Nitric oxide inhibits peroxynitrite-induced production of hydroxyecosatetraenoic acids and F2-isoprostanes in phosphatidylcholine liposomes. *Arch Biochem Biophys* 1996;330:193–198. [PubMed: 8651696]
247. Moore KP, Darley-Usmar V, Morrow J, Roberts LJ 2nd. Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. *Circ Res* 1995;77:335–341. [PubMed: 7614720]
248. Uppu RM, Squadrito GL, Pryor WA. Acceleration of peroxynitrite oxidations by carbon dioxide. *Arch Biochem Biophys* 1996;327:335–343. [PubMed: 8619624]
249. Denicola A, Freeman BA, Trujillo M, Radi R. Peroxynitrite reaction with carbon dioxide/bicarbonate: kinetics and influence on peroxynitrite-mediated oxidations. *Arch Biochem Biophys* 1996;333:49–58. [PubMed: 8806753]
250. Squadrito GL, Pryor WA. The nature of reactive species in systems that produce peroxynitrite. *Chem Res Toxicol* 1998;11:718–719. [PubMed: 9671532]
251. Gow A, Duran D, Thom SR, Ischiropoulos H. Carbon dioxide enhancement of peroxynitrite-mediated protein tyrosine nitration. *Arch Biochem Biophys* 1996;333:42–48. [PubMed: 8806752]
252. Sies H, Klotz LO, Sharov VS, Assmann A, Briviba K. Protection against peroxynitrite by selenoproteins. *Z Naturforsch [C]* 1998;53:228–232.
253. Roussyn I, Briviba K, Masumoto H, Sies H. Selenium-containing compounds protect DNA from single-strand breaks caused by peroxynitrite. *Arch Biochem Biophys* 1996;330:216–218. [PubMed: 8651699]
254. Epe B, Ballmaier D, Roussyn I, Briviba K, Sies H. DNA damage by peroxynitrite characterized with DNA repair enzymes. *Nucleic Acids Res* 1996;24:4105–4110. [PubMed: 8932358]
255. Briviba K, Roussyn I, Sharov VS, Sies H. Attenuation of oxidation and nitration reactions of peroxynitrite by selenomethionine, selenocystine and ebselen. *Biochem J* 1996;319(Pt 1):13–15. [PubMed: 8870642]

256. Forgione MA, Cap A, Liao R, Moldovan NI, Eberhardt RT, Lim CC, Jones J, Goldschmidt-Clermont PJ, Loscalzo J. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. *Circulation* 2002;106:1154–1158. [PubMed: 12196344]
257. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. *N Engl J Med* 2003;349:1605–1613. [PubMed: 14573732]
258. Bennett JS. Platelet-fibrinogen interactions. *Ann N Y Acad Sci* 2001;936:340–354. [PubMed: 11460491]
259. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. *J Clin Invest* 1997;100:350–356. [PubMed: 9218511]
260. Ludwig RJ, Schultz JE, Boehncke WH, Podda M, Tandi C, Krombach F, Baatz H, Kaufmann R, von Andrian UH, Zollner TM. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. *J Invest Dermatol* 2004;122:830–836. [PubMed: 15086572]
261. Kenet G, Freedman J, Shenkman B, Regina E, Brok-Simoni F, Holzman F, Vavva F, Brand N, Michelson A, Trolliet M, Loscalzo J, Inbal A. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. *Arterioscler Thromb Vasc Biol* 1999;19:2017–2023. [PubMed: 10446087]
262. Maddipati KR, Marnett LJ. Characterization of the major hydroperoxide-reducing activity of human plasma. Purification and properties of a selenium-dependent glutathione peroxidase. *J Biol Chem* 1987;262:17398–17403. [PubMed: 3693360]
263. Redondo PC, Salido GM, Rosado JA, Pariente JA. Effect of hydrogen peroxide on Ca²⁺ mobilisation in human platelets through sulphydryl oxidation dependent and independent mechanisms. *Biochem Pharmacol* 2004;67:491–502. [PubMed: 15037201]
264. Pariente JA, Camello C, Camello PJ, Salido GM. Release of calcium from mitochondrial and nonmitochondrial intracellular stores in mouse pancreatic acinar cells by hydrogen peroxide. *J Membr Biol* 2001;179:27–35. [PubMed: 11155207]
265. Moreau VH, Castilho RF, Ferreira ST, Carvalho-Alves PC. Oxidative damage to sarcoplasmic reticulum Ca²⁺-ATPase at submicromolar iron concentrations: evidence for metal-catalyzed oxidation. *Free Radic Biol Med* 1998;25:554–560. [PubMed: 9741592]

Figure 1.

Source of Superoxide Anion. The membrane-associated NAD(P)H oxidase enzyme complex catalyze the one-electron reduction of molecular oxygen using NAD(P)H as an electron donor, generating superoxide anion ($O_2^{\bullet-}$). The catalytic b₅₅₈-type cytochrome Nox subunit is bound to p22^{phox} in the plasma membrane, and they stabilize each other. The cytosolic subunits shown may also be required for full and sustained activation of the complex in vascular cells. Among the other sources of $O_2^{\bullet-}$ are the xanthine oxidoreductase enzyme system and 'uncoupled' eNOS. The mitochondrial electron transport chain produces $O_2^{\bullet-}$ by incomplete reduction of oxygen (O_2), mainly at complex I (NADH coenzyme Q reductase) and complex III (ubiquinol cytochrome *c* reductase).

Figure 2.

Biochemical Reactions of Reactive Oxygen Species. Superoxide anion reacts with itself to form hydrogen peroxide (H_2O_2) and oxygen (O_2) by spontaneous ($k \sim 5 \times 10^5 M^{-1} \cdot s^{-1}$ at pH 7.4) and enzymatic dismutation reactions ($k \sim 2 \times 10^9 M^{-1} \cdot s^{-1}$). Basal levels of H_2O_2 appear to regulate some signal transduction pathways, or are reduced to water (H_2O) by peroxiredoxins, glutathione peroxidases, or catalase. By the metal-catalyzed Fenton reaction, H_2O_2 forms the highly reactive hydroxyl radical ($\bullet OH$), which is the strongest oxidizing agent known. Superoxide anion reacts also with nitric oxide (NO) to form peroxynitrite ($ONOO^-$) at the diffusion limit with a rate ($k \sim 6.7 \times 10^9 M^{-1} \cdot s^{-1}$) that is faster than that of the superoxide dismutase (SOD) reaction.

Figure 3.

Common Chemical Reactions of Nitric Oxide. Synthesized from nitric oxide synthase (NOS), using L-arginine, nitric oxide (NO) reacts with a variety of targets, such as the ferrous iron (Fe²⁺) in heme moieties. In hemoglobin (Hb²⁺), the conversion to ferric iron (Fe³⁺) forms methemoglobin (Hb³⁺). Nitric oxide may also activate soluble guanylyl cyclase (sGC) and react with transition metals (M) to alter their valence (x). Nitric oxide also reacts with thiol groups (RSH) to produce S-nitrosothiols (RSNO). At rapid rates, NO reacts with superoxide anion (O₂^{-•}) to form peroxynitrite (ONOO⁻/ONOOH), which can form to nitrate (NO₃⁻). Nitric oxide can be reduced to nitrous oxide (N₂O) or oxidized to nitrite (NO₂⁻). Nitrite can react rapidly with oxygen, yielding nitrogen dioxide radical (•NO₂), which exists in equilibrium with the potent nitrosating agents dinitrogen trioxide (N₂O₃) and dinitrogen tetroxide (N₂O₄).

Figure 4.

Biological Consequences of Peroxynitrite Formation. Peroxynitrite formation has two important biological consequences: loss of bioactive nitric oxide (NO) and direct cytotoxic effects. Peroxynitrite and its conjugate acid can oxidize a variety of biomolecules with the consequence of protein modification or inactivation of ion channels. Peroxynitrite inactivates Mn-SOD, thereby increasing the flux of superoxide anion ($O_2^{\bullet-}$) available to react with nitric oxide and establishing an autocatalytic spiral of increasing mitochondrial peroxynitrite formation.

Table 1**Reactive Oxygen Species**

Oxidant	Characteristics	Function
Superoxide Anion ($O_2^{\cdot-}$)	One-electron reduction of O_2 Formed in many autooxidation reactions Electron transport chain NAD(P)H oxidase Mitochondrial respiration Glucose oxidase Xanthine oxidase Cytochrome P450s Cyclooxygenase Lipoxygenase Aldehyde oxidase Flavin dehydrogenase	Cause oxidative damage Alterations in gene transcription, posttranslational protein modification Changes in protein function and enzyme activities Release Fe^{2+} from iron-sulfur proteins and ferritin Inactivation of NO
Hydrogen Peroxide (H_2O_2)	Two-electron reduction of O_2 Dismutation of $O_2^{\cdot-}$ Xanthine oxidase Glucose oxidase	Lipid soluble Freely diffuses across membranes
Hydroxyl Radical ($\cdot OH$)	Three-electron reduction of O_2 Formation via Fenton reaction Decomposition of peroxynitrite	Extremely reactive Attacks most cellular components Modification of amino acids, carbohydrates, lipids, nucleic acids
Organic Hydroperoxide (ROOH)	Formed by radical reactions with cellular components	Reaction with lipids and nucleobases
Alkoxy ($RO\cdot$) and Peroxy Radicals ($ROO\cdot$)	Oxygen-centered organic radicals Formed in presence of oxygen by radical addition to double bonds Formed by hydrogen abstraction	Lipid peroxidation
Hypochlorous Acid (HOCl)	Formed from H_2O_2 by myeloperoxidase	Lipid soluble Highly reactive Oxidizes protein side chains, including thiol groups, amino groups, and methionine
Peroxynitrite ($OONO^-$)	Formed in a diffusion-controlled reaction between $O_2^{\cdot-}$ and $NO\cdot$ Protonation forms peroxynitrous acid, which can undergo homolytic cleavage to form hydroxyl radical and nitrogen dioxide	Lipid soluble Highly reactive Uncouple NOS by oxidizing cysteines involved in the zinc-thiolate cluster

Table 2**Biological Antioxidants**

Antioxidant	Characteristics	Function
Ascorbic Acid (Vitamin C)	Dietary sources Reduced form by maintained glutathione Reduction catalyzed by protein disulfide isomerase and glutaredoxins	Water soluble monosaccharide Free radical formation via Fenton reaction Protects vitamin E and GSH against oxidation
alpha-Tocopherol (Vitamin E)	Dietary sources	Lipid-soluble Chain-breaking radical scavenger family Reaction with lipid radicals Modulation of several enzymes in signal transduction
Glutathione (GSH)	Synthesized from cysteine, glutamate, glycine Recycled by reduction of GSSG by glutathione reductase	Major low-molecular-weight cysteine-containing peptide Eliminating lipid hydroperoxides and H ₂ O ₂ as a reducing co-substrate for glutathione peroxidases Involved in protein folding and ascorbate metabolism and generally preventing protein ⁻ SH groups from oxidation and cross-linkage
Superoxide Dismutase (SOD)	Three isoforms Contain metal ion cofactors (copper, zinc, manganese, iron)	Convert O ₂ ⁻ to H ₂ O ₂ and molecular oxygen
Catalase	Localized to peroxisomes	Reduction of H ₂ O ₂ to H ₂ O using either an iron or manganese cofactor
Peroxiredoxins (Prx)	Three subgroups Redox-active cysteine oxidized to a sulfenic acid	Reduction of H ₂ O ₂ to H ₂ O May remove thiyl radicals, causing ⁻ SH group oxidation
Thioredoxin	Redox-sensitive signaling functions Expression induced by oxidative stress	Reduction of disulfides in protein, peptides, and GSSG Directly reducing ROS
Glutathione Peroxidase	Five isoforms	Reduction of H ₂ O ₂ to H ₂ O Reduction of organic hydroperoxides Using GSH as a reductant Reduction of peroxynitrite
Heme Oxygenase	Two isoforms	Production of biliverdin and bilirubin Degradation of free heme Production of CO